Versatile intermediate for opioid derivatives, and preparation method therefor and use thereof
Through a common intermediate of opioid derivatives and its preparation method, hydrogenation, deprotection and substitution reactions, the problems of high raw materials in opioid synthesis and process dependence on opioid extracts are solved, and the cost of cheap and easy-to-get Diversified synthesis and high yields.
Patent Information
- Application Number
- PCT/CN2024/093980
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
The existing opioid synthesis process relies on opium poppy extracts, and there are problems such as climate-prone growth, high raw material costs and poor soil quality, and there is a lack of general chemical synthesis methods.
It provides an intermediate for opioid derivatives and its preparation method. Through hydrogenation, deprotection and substitution reactions, the synthesis of a variety of opioid drugs is achieved. The raw materials are cheap and easy to obtain, the synthesis steps are simple and the product yield is high.
The diversified synthesis of opioids is achieved, the cost of raw materials is reduced, the synthesis steps is simplified, and the product yield is improved, solving the problem of planting and extraction dependence of traditional processes.
Smart Images

Figure CN2024093980_21112024_PF_FP_ABST
Abstract
Description
A universal intermediate of opioid derivatives, its preparation method and its application
[0001] This application claims the benefit of Chinese Patent Application No. 2023105624725, filed on May 18, 2023. This application incorporates the entirety of the aforementioned Chinese Patent Application. Technical Field
[0002] The present invention relates to a general intermediate of opioid derivatives, a preparation method thereof and application thereof. Background Art
[0003] Naltrexone, naloxone, nalbuphine, oxymorphone and oxycodone are all important opioid drugs, widely used in postoperative analgesia and clinical practice. Among them, naltrexone and naloxone are opioid receptor antagonists, while nalbuphine, oxymorphone and oxycodone are opioid receptor agonists.
[0004] Naltrexone is a pure opioid receptor antagonist that has a blocking effect on μ-, δ-, and κ-opioid receptors. It can significantly weaken or completely block opioid receptors and has a long duration of action. It is a type of oral drug approved by the FDA in 1984 and can be used to block dependence on opioid drugs and alcohol.
[0005] Naloxone is a morphine receptor antagonist that blocks the effects of exogenous opioid receptor agonists and endogenous morphine-like substances, preventing or reversing central nervous system depressants such as respiratory depression and anti-shock effects caused by opioids. Its effects are rapid after intravenous injection and last for 1 to 4 hours. It can relieve opioid overdose and persistent respiratory depression after surgery, and can also be used for differential diagnosis of drug users.
[0006] Nalbuphine is a sedative psychotropic drug that targets opioid receptors. Its sedative effects are similar to those of morphine, with some respiratory depressant effects. It also has a capping effect and no cardiovascular side effects. It is commonly used clinically for postoperative analgesia.
[0007] Oxycodone is a semi-synthetic pure opioid receptor agonist. Its pharmacological effects and mechanisms of action are similar to those of morphine. It mainly exerts analgesic effects by stimulating opioid receptors in the central nervous system. It has moderate analgesic efficacy and is suitable for relieving moderate to severe pain. It also has anxiolytic and sedative effects.
[0008] Oxymorphone is an opioid receptor agonist with the same effects as morphine. It is commonly used clinically as an analgesic, boasting an analgesic effect 10 times that of morphine, but is also more addictive. It is indicated for the relief of moderate to severe pain, obstetric analgesia, and as an adjunct to anesthesia.
[0009] Because they are structurally similar, differing primarily in the substituents on the nitrogen atom at position 17, the development of a universal common intermediate for the divergent synthesis of a range of opioids is of great significance. Current opioid synthesis routes are all semi-synthetic routes based on opium poppy extracts, such as morphine, codeine, papaverine, and thebaine. These routes present uncertainties such as: 1) poppy cultivation is susceptible to climate change; 2) the high cost of raw material extraction; and 3) the deterioration of soil quality caused by poppy cultivation. Therefore, the development of chemical synthesis processes is an important supplement to the synthesis and production of opioids, and the development of universal common intermediates for the synthesis of opioid compounds is particularly important.
[0010] Summary of the Invention
[0011] The present invention addresses the technical problem of the single, existing method for synthesizing opioid derivatives. To address this issue, the present invention provides a universal intermediate for opioid derivatives, a method for preparing the intermediate, and its application. The intermediate provided herein can be used to synthesize a variety of opioid derivatives and offers one or more of the following advantages: readily available, inexpensive starting materials, simple synthesis steps, and high product yields.
[0012] The present invention solves the above technical problems through the following solutions.
[0013] The present invention provides a method for preparing a compound represented by Formula A8, comprising the following steps S11, S12 and S13:
[0014] S11: In a solvent, in the presence of a catalyst, the compound represented by Formula 7 is subjected to a hydrogenation reaction represented by the following formula with hydrogen to obtain a compound represented by Formula 8-1:
[0015] S12: In a solvent, in the presence of a deprotection agent, the compound represented by Formula 8-1 undergoes a deprotection reaction as shown in the following formula to obtain a compound represented by Formula 8-2.
[0016] S13: In a solvent, in the presence of a base, the compound represented by Formula 8-2 and the compound represented by Formula SM1 undergo a substitution reaction as shown below to obtain a compound represented by Formula A8.
[0017] Wherein, X is halogen, R 1 C 1-4 Alkyl or one or more R1-1 Substituted C 1-4 Alkyl; R 1-1 is a 3-6 membered cycloalkyl group or a C 2- 4 alkenyl.
[0018] In step S11, the conditions, reagent types and reagent amounts of the hydrogenation reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0019] In step S11, the solvent may be an alcohol solvent, such as methanol and / or ethanol; another example is methanol.
[0020] In step S11, the molar volume ratio of the compound represented by Formula 7 to the solvent may be (0.1-0.3) mol:1L, for example, 0.13 mol:1L.
[0021] In step S11, the catalyst may be Raney nickel and / or palladium catalyst, such as palladium catalyst, for example 10% palladium / carbon, where "%" is the mass percentage of palladium to the total mass of palladium and carbon.
[0022] In step S11, the mass ratio of the catalyst to the compound represented by Formula 7 may be (0.01-1):1, for example (0.05-0.5):1, and for example 0.1:1.
[0023] In step S11, the pressure of the hydrogenation reaction may be 1-10 atm, such as 1-3 atm, and another example is 2 atm.
[0024] In step S11, the temperature of the hydrogenation reaction may be 10-45°C, such as 20-30°C, and another example is 30°C.
[0025] In step S11, the progress of the hydrogenation reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined as the disappearance or no-reaction of the compound represented by Formula 7. The hydrogenation reaction time can be 1-10 h, for example, 3-6 h, and for example, 4 h.
[0026] In step S11, after the hydrogenation reaction is completed, the following post-processing steps may be further included. The post-processing steps are conventional post-processing operations for such reactions, such as filtration and concentration.
[0027] In step S11, after the hydrogenation reaction is completed, the next reaction can be directly carried out without purification.
[0028] In step S12, the conditions, reagent types and reagent amounts of the deprotection reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0029] In step S12, the solvent may be an alcohol solvent, such as methanol and / or ethanol; another example is methanol.
[0030] In step S12, the molar volume ratio of the compound represented by Formula 8-1 to the solvent may be (0.01-1) mol:1L, for example, 0.05 mol:1L.
[0031] In step S12, the deprotection reagent may be an acid, such as an inorganic acid, or hydrochloric acid.
[0032] The acid may be an acid solution, for example, a 4 mol / L hydrochloric acid methanol solution.
[0033] In step S12, the molar ratio of the acid to the compound represented by Formula 8-1 may be (1-100):1, for example (30-60):1, and for example 43:1.
[0034] In step S12, the temperature of the deprotection reaction may be 0-20°C, for example 10°C.
[0035] In step S12, the progress of the deprotection reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS). The reaction endpoint is generally determined when the compound represented by Formula 8-1 disappears or ceases to react. The deprotection reaction time can be 0.5-3 h, for example, 1.5 h.
[0036] In step S12, after the deprotection reaction is completed, the following post-processing step may be further included. The post-processing step is a conventional post-processing operation for this type of reaction, such as concentration.
[0037] In step S12, after the deprotection reaction is completed, the next reaction can be directly performed without purification.
[0038] In one embodiment, in X, the halogen may be F, Cl, Br or I, such as Br.
[0039] In one embodiment, the R 1 In the C 1-4 Alkyl and said one or more R 1-1 Substituted C 1-4 C in the alkyl group 1-4 Alkyl groups independently may be methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl or isobutyl, for example methyl.
[0040] In one embodiment, the R 1 In the above, one or more R 1-1 Substituted C 1-4 Alkyl is an R 1-1 Substituted C 1-4alkyl.
[0041] In one embodiment, the R 1-1 In the embodiment, the 3-6 membered cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, for example, cyclopropyl or cyclobutyl.
[0042] In one embodiment, the R 1-1 In the C 2-4 The alkenyl group may be ethenyl, propenyl or butenyl, for example ethenyl.
[0043] In one scenario, R 1 Methyl, For example
[0044] In one embodiment, X is Br.
[0045] In one embodiment, in step S13, the compound represented by formula SM1 is The compound shown in formula A8 is
[0046] In step S13, the conditions, reagent types and reagent amounts of the substitution reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0047] In step S13, the solvent may be a mixed solvent of an organic solvent and water.
[0048] The organic solvent may be a pyrrolidone organic solvent, such as N-methylpyrrolidone.
[0049] The volume ratio of the organic solvent to water may be (1-10):1, for example (4-6):1, and for example 5:1.
[0050] In step S13, the molar volume ratio of the compound represented by Formula 8-2 to the solvent may be (0.01-0.3) mol:1L, for example, 0.19 mol:1L.
[0051] In step S13, the base may be an organic base, such as an organic amine, and another example is triethylamine.
[0052] In step S13, the molar ratio of the base to the compound represented by Formula 8-2 may be (1-10):1, for example (4-6):1, and for example 5:1.
[0053] In step S13, the molar ratio of the compound represented by formula SM1 to the compound represented by formula 8-2 may be (1-3):1, for example (1-1.5):1, and for example 1.3:1.
[0054] In step S13, the substitution reaction may be performed under the protection of an inert gas, and the inert gas may be a conventional protective gas in the art, such as nitrogen and / or argon, for example nitrogen.
[0055] In step S13, the temperature of the substitution reaction may be 60-90°C, for example 70°C.
[0056] In step S13, the progress of the substitution reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS). The reaction endpoint is generally determined when the compound represented by Formula 8-2 disappears or ceases to react. The substitution reaction time can be 1-6 hours, for example, 4 hours.
[0057] In step S13, after the substitution reaction is completed, the following post-processing steps may be further included. The post-processing steps are conventional post-processing operations for this type of reaction, for example, including one or more of extraction, drying, concentration, and purification. The solvent for the extraction may be dichloromethane. The drying agent may be anhydrous sodium sulfate. The concentration may be performed by vacuum distillation. The purification may be performed by column chromatography. The eluent for the column chromatography may be a mixed solvent of dichloromethane and methanol, for example, a volume ratio of dichloromethane to methanol of 50:1.
[0058] The preparation method of the compound shown in Formula A8 also includes the preparation method of the compound shown in Formula 7, which specifically includes the following steps S10: in a solvent, in the presence of an oxidant, the compound shown in Formula 6 undergoes an oxidation reaction as shown in the following formula to obtain the compound shown in Formula 7,
[0059] In step S10, the conditions, reagent types and reagent amounts of the oxidation reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0060] In step S10, the solvent may be one or more of an organic acid solvent, a chlorinated alkane solvent, and water, for example, a mixed solvent of an organic acid solvent, a chlorinated alkane solvent, and water.
[0061] The chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, for example, dichloromethane.
[0062] The organic acid solvent may be formic acid and / or acetic acid, such as acetic acid.
[0063] The ratio of the mixed solvent is not particularly limited, as long as the solubility is good and the reaction is not affected. The ratio of the mixed solvent in the present invention is preferably as follows.
[0064] In the mixed solvent, the volume ratio of the chlorinated alkane solvent to water may be (1-10):1, for example, 7:1.
[0065] In the mixed solvent, the volume ratio of the organic acid solvent to water may be (1-10):1, for example, 2:1.
[0066] In step S10, the molar volume ratio of the compound represented by Formula 6 to the solvent may be (0.01-1) mol:1 L; for example, (0.01-0.3) mol:1 mL, and another example is 0.13 mol:1 L.
[0067] The oxidizing agent may be selected from one or more of hydrogen peroxide, m-chloroperbenzoic acid and magnesium monoperoxyphthalate hexahydrate, such as magnesium monoperoxyphthalate hexahydrate (MMPP).
[0068] In step S10, the molar ratio of the oxidant to the compound represented by Formula 6 may be (1-5):1, for example (1.1-2):1, and for example 1.5:1.
[0069] In step S10, the temperature of the oxidation reaction may be -20°C-25°C, such as 0°C-20°C, and another example is 15°C.
[0070] In step S10, the oxidation reaction may further include the following steps: mixing the compound represented by Formula 6 and the solvent, and adding the oxidant.
[0071] The oxidant may be added at -5-5°C, for example, at 0°C.
[0072] In step S10, the progress of the oxidation reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined when the compound represented by Formula 6 disappears or no longer reacts. The oxidation reaction time can be 1-5 hours, for example, 3 hours.
[0073] In step S10, after the oxidation reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for such reactions, for example, one or more of quenching, extraction, drying, concentration, and purification. The quenching solvent may be an aqueous sodium thiosulfate solution. The extraction solvent may be dichloromethane. The drying agent may be anhydrous sodium sulfate. The concentration may be performed by vacuum distillation. The purification may be performed by column chromatography, and the eluent for the column chromatography may be a mixed solvent of dichloromethane and ethyl acetate, for example, a volume ratio of dichloromethane to ethyl acetate of 4:1.
[0074] In the preparation method of the compound shown in Formula A8, the preparation method of the compound shown in Formula 7 also includes the preparation method of the compound shown in Formula 6, which specifically includes the following steps S9: in a solvent, in the presence of a cyclization reagent, the compound shown in Formula 6-2 undergoes a cyclization reaction as shown in the following formula to obtain the compound shown in Formula 6,
[0075] In step S9, the conditions, reagent types and reagent amounts of the cyclization reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0076] In step S9, the cyclization reaction can be carried out under the protection of an inert gas. The inert gas can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0077] In step S9, the solvent may be a chlorinated alkane solvent, which may be one or more of dichloromethane, 1,2-dichloroethane, and chloroform, such as dichloromethane.
[0078] In step S9, the molar volume ratio of the compound represented by Formula 6-2 to the solvent may be (0.1-2) mol:1L, for example, 0.9 mol:1L.
[0079] In step S9, the cyclization reagent may be one or more of N,N-dimethylformamide dimethyl acetal (DMFDMA), p-toluic acid, sodium methoxide and sodium ethoxide, for example, N,N-dimethylformamide dimethyl acetal.
[0080] In step S9, the molar ratio of the cyclization reagent to the compound represented by Formula 6-2 can be (1-5):1, for example (1-3):1, and for example 1.5:1.
[0081] In step S9, the temperature of the cyclization reaction may be 20-35°C, for example 25°C.
[0082] In step S9, the progress of the cyclization reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined when the compound represented by Formula 6-2 disappears or no longer reacts. The cyclization reaction time can be 1-5 hours, for example, 3 hours.
[0083] In step S9, after the cyclization reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of extraction, drying, concentration, and purification. The solvent for the extraction may be a mixed solvent of petroleum ether and ethyl acetate, for example, the volume ratio of petroleum ether to ethyl acetate is 6:1. The drying desiccant may be anhydrous sodium sulfate. The concentration may be distillation under reduced pressure. The purification may be crystallization. The solvent for the crystallization may be a mixed solvent of methanol and water, for example, the volume ratio of methanol to water is 4:1. The temperature for the crystallization may be -20-0°C, for example, -10°C.
[0084] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 6 also includes the preparation method of the compound represented by Formula 6-2, which specifically includes the following steps S8: in a solvent, in the presence of a reducing agent, the compound represented by Formula 6-1 undergoes a reduction reaction as shown in the following formula to obtain the compound represented by Formula 6-2,
[0085] In step S8, the conditions, reagent types and reagent amounts of the reduction reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0086] In step S8, the reduction reaction can be carried out under the protection of an inert gas. The inert gas can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0087] In step S8, the solvent may be an ether solvent, such as tetrahydrofuran.
[0088] In step S8, the molar volume ratio of the compound represented by Formula 6-1 to the solvent may be (0.1-2) mol:1L, for example, 0.22 mol:1L.
[0089] In step S8, the reducing agent can be selected from one or more of alkali metal borohydrides, lithium aluminum hydride and diisobutylaluminum hydride, for example, diisobutylaluminum hydride, and another example is a tetrahydrofuran solution of diisobutylaluminum hydride.
[0090] In step S8, the molar ratio of the reducing agent to the compound represented by Formula 6-1 may be (1-5):1, for example (1-3):1, and for example 2:1.
[0091] In step S8, the temperature of the reduction reaction may be -5-35°C, such as 10-30°C, and another example is 15°C.
[0092] In step S8, the progress of the reduction reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined as the disappearance or non-reaction of the compound represented by Formula 6-1. The reduction reaction time can be 0.1-2 h, for example, 0.5 h.
[0093] Step S8 may further include the following steps: mixing the compound represented by Formula 6-1 with the solvent, adding the reducing agent, and performing the reduction reaction.
[0094] The reducing agent may be added at -25-5°C, for example, at -20°C or 5°C.
[0095] In step S8, after the reduction reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of quenching, extraction, drying, and concentration. The quenching solvent may be an aqueous sodium hydroxide solution, for example, an aqueous sodium hydroxide solution with a molar concentration of 4N. The extraction solvent may be dichloromethane. The drying agent may be anhydrous sodium sulfate. The concentration may be distillation under reduced pressure.
[0096] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 6-2 also includes the preparation method of the compound represented by Formula 6-1, which specifically includes the following step S7: in a solvent, in the presence of a hydrogen source and a palladium catalyst, the compound represented by Formula 5 is subjected to a debenzylation reaction as shown in the following formula to obtain the compound represented by Formula 6-1,
[0097] In step S7, the conditions, reagent types and reagent amounts of the debenzylation reaction can be conventional conditions, reagent types and reagent amounts for such reactions in the art, and the following are preferred in the present invention.
[0098] In step S7, the debenzylation reaction can be carried out under the protection of an inert gas, which can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0099] In step S7 , the solvent may be an ether solvent or an amide solvent, such as an amide solvent, and another example is N,N-dimethylacetamide.
[0100] In step S7, the molar volume ratio of the compound represented by Formula 5 to the solvent may be (0.1-1) mol:1L, for example, 0.4 mol:1L.
[0101] In step S7, the hydrogen source may be hydrogen gas and / or sodium hydride, such as sodium hydride.
[0102] In step S7, the molar ratio of the hydrogen source to the compound represented by Formula 5 may be (1-2):1, for example, 1.5:1.
[0103] In step S7, the palladium catalyst can be selected from one or more of dry palladium carbon, palladium hydroxide, palladium chloride and palladium acetate, such as palladium chloride.
[0104] In step S7, the molar ratio of the palladium catalyst to the compound represented by Formula 5 may be (0.01-0.5):1, for example, 0.05:1.
[0105] In step S7, the temperature of the debenzylation reaction can be 10-30°C, for example, 25°C.
[0106] In step S7, the progress of the debenzylation reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined as the disappearance or no-reaction of the compound represented by Formula 5. The debenzylation reaction time can be 1-20 h, for example, 10 h.
[0107] In step S7, after the debenzylation reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of quenching, extraction, drying, and concentration. The quenching solvent may be water. The extraction solvent may be ethyl acetate. The drying agent may be anhydrous sodium sulfate. The concentration may be distillation under reduced pressure.
[0108] In the preparation method of the compound shown in Formula A8, the preparation method of the compound shown in Formula 6-1 also includes the preparation method of the compound shown in Formula 5, which specifically includes the following step S6: in a solvent, in the presence of a palladium catalyst, a phosphine ligand and a base, the compound shown in Formula 4 undergoes a dearomatization cyclization reaction as shown in the following formula to obtain the compound shown in Formula 5,
[0109] In step S6, the conditions, reagent types and reagent amounts of the dearomatization cyclization reaction can be the conventional conditions, reagent types and reagent amounts of such reactions in the art, and the present invention preferably has the following conditions.
[0110] In step S6, the dearomatization cyclization reaction can be carried out under the protection of an inert gas. The inert gas can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0111] In step S6, the solvent may be a sulfoxide solvent and / or an amide solvent, such as an amide solvent. The amide solvent may be one or more of N-pyrrolidone, N,N-dimethylformamide (DMF), and N,N-dimethylacetamide (DMA), such as N,N-dimethylacetamide.
[0112] In step S6, the molar volume ratio of the compound represented by Formula 4 to the solvent may be (0.01-1) mol:1L, for example, 0.29 mol:1L.
[0113] In step S6, the palladium catalyst may be one or more of palladium chloride, bis(acetonitrile)palladium chloride, palladium trifluoromethanesulfonate and palladium acetate, for example, palladium chloride.
[0114] In step S6, the molar ratio of the palladium catalyst to the compound represented by Formula 4 may be (0.01-0.5):1, for example, 0.04:1.
[0115] In step S6, the phosphine ligand may be one or more of tri-tert-butylphosphine, tricyclohexylphosphine, di(1-adamantyl)-n-butylphosphine, diadamantylisopropylphosphine and diadamantylpropylphosphine, for example, di(1-adamantyl)-n-butylphosphine.
[0116] In step S6, the molar ratio of the phosphine ligand to the compound represented by Formula 4 may be (0.01-0.5):1, for example, 0.06:1.
[0117] In step S6, the base may be an alkali metal carbonate, such as potassium carbonate or potassium phosphate.
[0118] In step S6, the molar ratio of the base to the compound represented by Formula 4 may be (1-5):1, for example, 2:1.
[0119] In step S6, the dearomatization cyclization reaction temperature may be 100°C-180°C, for example 140°C.
[0120] In step S6, the progress of the dearomatization reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LCMS), and the endpoint is generally the disappearance or no further reaction of the compound represented by Formula 4. The dearomatization reaction time can be 3-10 hours, for example, 6 hours.
[0121] In step S6, after the dearomatization reaction is completed, the following post-processing steps may be further included. The post-processing steps are conventional post-processing operations for such reactions in the art, for example, including one or more of filtration, concentration, drying, and purification. The concentration may be vacuum distillation. The purification may be column chromatography, and the eluent for the column chromatography may be a mixed solvent of dichloromethane and methanol, for example, the volume ratio of dichloromethane to methanol is (150-100):1.
[0122] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 5 also includes the preparation method of the compound represented by Formula 4, which specifically includes the following steps S5: in a solvent, the compound represented by Formula 4-3' is reacted with di-tert-butyl carbonic anhydride as shown in the following formula to obtain the compound represented by Formula 4,
[0123] In step S5, the reaction conditions, reagent types and reagent amounts can be the conventional conditions, reagent types and reagent amounts for such reactions in the art, and the present invention preferably uses the following.
[0124] In step S5, the solvent may be a chlorinated alkane solvent, and the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane.
[0125] In step S5, the molar volume ratio of the compound represented by Formula 4-3' to the solvent may be (0.01-1) mol:1L, for example, 0.09 mol:1L.
[0126] In step S5, the molar ratio of the di-tert-butyl carbonate to the compound represented by formula 4-3' can be (1-3):1, for example, 1.08:1.
[0127] In step S5, the reaction temperature may be 10-30°C, for example 25°C.
[0128] In step S5, the progress of the reaction can be monitored by conventional monitoring methods in the art (such as TLC or LC-MS), and the reaction endpoint is generally determined as the disappearance or non-reaction of the compound represented by formula 4-3'. The reaction time can be 1-5 hours, for example, 3 hours.
[0129] In step S5, after the reaction is completed, the following post-processing steps may be further included. The post-processing steps are conventional post-processing operations for such reactions in the art, for example, including one or more of concentration, crystallization, filtration, and drying. The concentration may be distillation under reduced pressure. The solvent for the crystallization may be methanol. The drying may be oven drying.
[0130] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 4 also includes the preparation method of the compound represented by Formula 4-3', which specifically includes the following steps S4': in a solvent, the compound represented by Formula 4-3 reacts with a base as shown in the following formula to obtain the compound represented by Formula 4-3',
[0131] In step S4', the reaction conditions, reagent types and reagent dosages may be conventional conditions, reagent types and reagent dosages for such reactions in the art, and the preferred ones in the present invention are as follows.
[0132] In step S4', the solvent may be a chlorinated hydrocarbon solvent, and the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane, and chloroform, such as dichloromethane.
[0133] In step S4', the molar volume ratio of the compound represented by Formula 4-3 to the solvent may be (0.01-1) mol:1L, for example, 0.13 mol:1L.
[0134] In step S4', the base may be an inorganic base, such as potassium bicarbonate, or an aqueous solution of potassium bicarbonate.
[0135] In step S4', the molar ratio of the base to the compound represented by formula 4-3 can be (1-10):1, for example (4-6):1, and for example 5:1.
[0136] In step S4', the reaction temperature may be 20-30°C, for example 25°C.
[0137] In step S4', the progress of the reaction can be monitored by conventional monitoring methods in the art (such as TLC or LC-MS), and the reaction endpoint is generally determined as the disappearance or no further reaction of the compound represented by Formula 4-3. The reaction time can be 0.3-12 hours, for example, 1 hour.
[0138] In step S4', after the reaction is completed, the following post-processing step may be further included: extraction. The extraction solvent may be dichloromethane.
[0139] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 4-3' also includes the preparation method of the compound represented by Formula 4-3, which specifically includes the following step S4: in a solvent, the compound represented by Formula 4-2 and D-(+)-di-p-methylbenzoyltartaric acid (DTTA) react as shown in the following formula to obtain the compound represented by Formula 4-3,
[0140] In step S4, the reaction may be carried out in an open system, and the open system may be an air system.
[0141] In step S4, the solvent may be an alcohol solvent, for example, one or more selected from methanol, ethanol and isopropanol; another example is methanol.
[0142] In step S4, the molar volume ratio of the compound represented by Formula 4-2 to the solvent may be (0.1-1) mol:1L, for example, 0.62 mol:1L or 0.6 mol:1.
[0143] In step S4, the molar ratio of the D-(+)-di-p-methylbenzoyltartaric acid to the compound represented by formula 4-2 may be (1-3):1, for example (0.9-1.5):1, or for example 1.05:1 or 1.07:1.
[0144] In step S4, the reaction temperature may be 50-100°C, such as 70-100°C, and another example is 85°C.
[0145] In step S4, the progress of the reaction can be monitored using conventional monitoring methods in the art (e.g., TLC or LC-MS), and the reaction endpoint is generally determined as the disappearance or non-reaction of the compound represented by Formula 4-2. The reaction time can be 3-12 hours, for example, 8 hours.
[0146] Step S4 may further include the following steps: mixing the compound represented by Formula 4-2 with the solvent, and then adding the D-(+)-di-p-methylbenzoyltartaric acid.
[0147] In step S4, after the reaction is completed, the following post-processing step may be further included: filtration.
[0148] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 4-3 also includes the preparation method of the compound represented by Formula 4-2, which specifically includes the following step S3: in a solvent, in the presence of an organic base, the compound represented by Formula 4-1 is subjected to a decarbamate protection reaction as shown in the following formula to obtain the compound represented by Formula 4-2,
[0149] The organic base is potassium alkoxide and / or sodium alkoxide.
[0150] In step S3, the solvent may be an ether solvent and / or a chlorinated hydrocarbon solvent, such as an ether solvent.
[0151] The ether solvent may be one or more of tetrahydrofuran, 1,4-dioxane, diethyl ether and methyl tert-butyl ether, such as tetrahydrofuran.
[0152] In step S3, the molar volume ratio of the compound represented by Formula 4-1 to the solvent may be (0.01-3) mol:1L, for example (0.1-1) mol:1L, for example 0.31 mol:1L or 0.35 mol:1L.
[0153] In step S3, the potassium alkoxide may be potassium methoxide, potassium ethoxide or potassium tert-butoxide, for example, potassium tert-butoxide. The sodium alkoxide may be sodium methoxide, sodium ethoxide or sodium tert-butoxide.
[0154] In step S3, the reaction system may further include an inorganic base, which may be potassium hydroxide and / or sodium hydroxide, for example, potassium hydroxide.
[0155] The molar ratio of the organic base to the inorganic base may be (0.5-2):1, for example 1:1.
[0156] In step S3, the molar ratio of the organic base to the compound represented by Formula 4-1 may be (0.05-5):1, for example (1-3):1, and for example 2:1 or 1.77:1.
[0157] In step S3, the temperature of the decarbamate protection reaction may be 60-80°C, for example 70°C.
[0158] Step S3 may further include the following steps: mixing the compound represented by Formula 4-1 with the solvent, and then adding the organic base.
[0159] In step S3, the progress of the decarbamate protection reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the end point is generally the disappearance or no further reaction of the compound represented by Formula 4-1. The decarbamate protection reaction time can be 5-24 hours, for example, 8 hours.
[0160] In step S3, after the decarbamate protection reaction is completed, the following post-processing steps may be further included, wherein the post-processing steps include one or more of quenching, extraction, and concentration. The quenching solvent may be water. The extraction solvent may be dichloromethane. The concentration may be concentrated under reduced pressure.
[0161] The method for preparing the compound of Formula A8, the method for preparing the compound of Formula 4-2 also includes the method for preparing the compound of Formula 4-1, which specifically includes the following steps S2: in a solvent, in the presence of a base, the compound of Formula 3' is subjected to the reaction shown in the following formula to obtain the compound of Formula 4-1,
[0162] In step S2, the reaction conditions, reagent types and reagent amounts can be the conventional conditions, reagent types and reagent amounts for such reactions in the art, and the present invention preferably follows.
[0163] In step S2, the solvent may be an alcohol solvent, such as methanol and / or ethanol, for example ethanol.
[0164] In step S2, the molar volume ratio of the compound represented by Formula 3 to the solvent may be (0.1-1) mol:1L, for example, 0.62 mol:1L.
[0165] In step S2, the base may be an inorganic base, such as potassium hydroxide.
[0166] In step S2, the molar ratio of the base to the compound represented by Formula 3 may be (1-3):1, for example, 2:1.
[0167] In step S2, the reaction temperature may be 30°C-70°C, for example 50°C.
[0168] In step S2, the progress of the reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the end point is generally the disappearance or no further reaction of the compound represented by Formula 3. The reaction time can be 1-10 hours, for example, 3 hours.
[0169] In step S2, after the reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of quenching, beating, and drying. The quenching solvent may be water. The drying may be oven drying. The beating solvent may be methanol.
[0170] The preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 4-1 also includes the preparation method of the compound represented by Formula 3', which specifically includes the following steps S2': in a solvent, in the presence of a base, the compound represented by Formula 3 and benzyl bromide react as shown in the following formula to obtain the compound represented by Formula 3',
[0171] In step S2', the reaction conditions, reagent types and reagent amounts may be conventional conditions, reagent types and reagent amounts for such reactions in the art, and the preferred ones in the present invention are as follows.
[0172] In step S2', the reaction can be carried out under the protection of an inert gas. The inert gas can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0173] In step S2 ′, the solvent may be an amide solvent, such as N,N-dimethylformamide (DMF) and / or N,N-dimethylacetamide (DMA), or N,N-dimethylformamide.
[0174] In step S2', the molar volume ratio of the compound represented by Formula 3 to the solvent may be (0.1-1) mol:1L, for example, 0.62 mol:1L.
[0175] In step S2', the base may be an alkali metal carbonate, such as potassium carbonate.
[0176] In step S2', the molar ratio of the base to the compound represented by Formula 3 may be (1-3):1, for example, 2:1.
[0177] In step S2', the molar ratio of the benzyl bromide to the compound represented by Formula 3 may be (1-3):1, for example, 2:1.
[0178] In step S2', the reaction temperature may be 10°C-30°C, for example 25°C.
[0179] In step S2', the progress of the reaction can be monitored by conventional monitoring methods in the art (eg, TLC or LCMS), and the end point is generally the disappearance or no further reaction of the compound represented by Formula 3. The reaction time can be 3-10 hours, for example, 6 hours.
[0180] In step S2', after the reaction is completed, the following post-processing step may be further included. The post-processing step may be a conventional post-processing operation for such a reaction, such as crystallization. The solvent for the crystallization may be water.
[0181] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 3' also includes the preparation method of the compound represented by Formula 3, which specifically includes the following steps S1: in a solvent, in the presence of an acid, the compound represented by Formula 1 and the compound represented by Formula 2 undergo a condensation cyclization reaction as shown in the following formula to obtain the compound represented by Formula 3,
[0182] The acid is one or more of methanesulfonic acid, trifluoroacetic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate.
[0183] In step S1, the condensation cyclization reaction can be carried out in an open system, which can be an air system.
[0184] In step S1, the solvent is a conventional solvent for this type of reaction in the art, and the solvent can be a chlorinated alkane and / or an amide, for example, a chlorinated alkane organic solvent.
[0185] The chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, for example, dichloromethane.
[0186] In step S1, the molar volume ratio of the compound represented by Formula 1 to the solvent may be (0.1-5) mol:1L, for example (0.1-2) mol:1L, and another example is 0.78 mol:1L.
[0187] In step S1, the molar ratio of the acid to the compound represented by Formula 1 may be (1-5):1, for example (1-3):1, and for example 2:1.
[0188] In step S1, the acid may be p-toluenesulfonic acid and / or p-toluenesulfonic acid monohydrate, for example, p-toluenesulfonic acid monohydrate.
[0189] In step S1, the molar ratio of the compound represented by Formula 2 to the compound represented by Formula 1 may be (1-1.5):1, for example, 1.4:1.
[0190] In step S1, the temperature of the condensation cyclization reaction can be 0-30°C, for example, 25°C.
[0191] In step S1, the progress of the condensation cyclization reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the end point is generally the disappearance or no further reaction of the compound represented by Formula 1. The reaction time can be 2-24 hours, for example, 16 hours.
[0192] In step S1, after the reaction is completed, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of quenching, drying, concentration, and purification. The quenching solvent may be water. The drying desiccant may be anhydrous sodium sulfate. The concentration may be vacuum distillation. The purification may be recrystallization, and the recrystallization solvent may be a mixed solvent of ethyl acetate and petroleum ether, for example, in a volume ratio of ethyl acetate to petroleum ether of 2:1.
[0193] In the preparation method of the compound represented by Formula A8, the preparation method of the compound represented by Formula 3 also includes the preparation method of the compound represented by Formula 1, which specifically includes the following steps S1-1: In a solvent, the compound represented by Formula 1-2 and ethyl chloroformate react as shown in the following formula to obtain the compound represented by Formula 1,
[0194] In step S1-1, the solvent may be a conventional solvent for such reactions in the art, such as an ether solvent, or tetrahydrofuran.
[0195] In step S1-1, the molar volume ratio of the compound represented by Formula 1-2 to the solvent can be (0.1-5) mol:1L, for example (0.1-1) mol:1L, and another example is 0.1 mol:1L.
[0196] In step S1-1, the molar ratio of the ethyl chloroformate to the compound represented by Formula 1-2 may be (1-5):1, for example (1-3):1, and for example 2.2:1.
[0197] In step S1-1, the reaction temperature may be 10-30°C, for example 25°C.
[0198] In step S1-1, the progress of the reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the end point is generally the disappearance or no further reaction of the compound represented by Formula 1. The reaction time can be 1-30 hours, for example, 16 hours.
[0199] In step S1-1, after completion of the reaction, the following post-processing steps may be further included. The post-processing steps may be conventional post-processing operations for this type of reaction, for example, one or more of quenching, extraction, drying, and concentration. The quenching solvent may be water. The drying agent may be anhydrous sodium sulfate. The concentration may be vacuum distillation. The purification may be recrystallization, and the extraction solvent may be ethyl acetate.
[0200] The present invention provides a method for preparing a compound as shown in Formula A9, which comprises the following step S14: in a solvent, in the presence of a demethylation agent, subjecting the compound as shown in Formula A8 to a demethylation reaction as shown in the following formula to obtain a compound as shown in Formula A9,
[0201] The method for preparing the compound represented by Formula A9 also includes the method for preparing the compound represented by Formula A8, which specifically includes the following steps S11, S12 and S13:
[0202] S11: In a solvent, in the presence of a catalyst, the compound represented by Formula 7 is subjected to a hydrogenation reaction represented by the following formula with hydrogen to obtain a compound represented by Formula 8-1:
[0203] S12: In a solvent, in the presence of a deprotection agent, the compound represented by Formula 8-1 undergoes a deprotection reaction as shown in the following formula to obtain a compound represented by Formula 8-2.
[0204] S13: In a solvent, in the presence of a base, the compound represented by Formula 8-2 and the compound represented by Formula SM1 undergo a substitution reaction as shown below to obtain a compound represented by Formula A8.
[0205] Among them, X and R 1 The definition of is as described in any one of the present invention.
[0206] In one embodiment, in step S14, the compound represented by formula A8 is The compound shown in formula A9 is
[0207] In step S14, the reaction conditions, reagent types and reagent amounts of the reaction can be the conventional conditions, reagent types and reagent amounts of this type of reaction in the art, and the present invention preferably has the following.
[0208] In step S14, the solvent may be a chlorinated alkane, and the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane.
[0209] In step S14, the molar volume ratio of the compound represented by Formula A8 to the solvent may be (0.01-0.1) mol:1L, for example, 0.045 mol:1L.
[0210] In step S14, the demethylation reaction can be carried out under the protection of an inert gas. The inert gas can be a conventional protective gas in the art, such as nitrogen and / or argon, and another example is nitrogen.
[0211] In step S14, the demethylation agent may be boron trichloride and / or boron tribromide, for example, boron tribromide.
[0212] In step S14, the molar ratio of the demethylation reagent to the compound represented by formula A8 can be (5-10):1, for example (6-8):1, and for example 7:1.
[0213] In step S14, the temperature of the demethylation reaction may be -20-25°C, for example, 10°C.
[0214] In step S14, the progress of the demethylation reaction can be monitored by conventional monitoring methods in the art (e.g., TLC or LCMS), and the reaction endpoint is generally determined to be the disappearance or non-reaction of the compound shown in Formula 8. The demethylation reaction time can be 1-5 h, for example, 2 h.
[0215] In step S14, after the demethylation reaction is completed, the following post-processing steps may be further included. The post-processing steps are conventional post-processing operations for this type of reaction, for example, including one or more of quenching, pH adjustment, extraction, drying, concentration, and purification. The solvent for the quenching may be a saturated aqueous solution of ammonium chloride. The solvent for the pH adjustment may be a saturated 10% aqueous solution of NaHCO3. The solvent for the extraction may be dichloromethane. The drying agent may be anhydrous sodium sulfate. The concentration may be vacuum distillation. The purification may be column chromatography. The eluent for the column chromatography may be a mixed solvent of dichloromethane and methanol, for example, a volume ratio of dichloromethane to methanol of 50:1.
[0216] The conditions and operations of the preparation method of the compound represented by Formula A8 may be as described in any one of the present inventions.
[0217] The present invention provides a method for preparing a compound as shown in Formula 4-3', comprising the following steps S4': in a solvent, the compound as shown in Formula 4-3 reacts with a base as shown in the following formula to obtain a compound as shown in Formula 4-3',
[0218] The conditions and operations of the preparation method of the compound represented by Formula 4-3' can be as described in any one of the present inventions.
[0219] The preparation method of the compound shown in Formula 4-3' may also include the preparation method of the compound shown in Formula 4-3, which specifically includes the following step S4: in a solvent, the compound shown in Formula 4-2 and D-(+)-di-p-methylbenzoyltartaric acid (DTTA) react as shown in the following formula to obtain the compound shown in Formula 4-3,
[0220] The conditions and operations of the preparation method of the compound represented by Formula 4-3 may be as described in any one of the present inventions.
[0221] The present invention provides a method for preparing a compound as shown in Formula 4-2, comprising the following step S3: in a solvent, in the presence of an organic base, the compound as shown in Formula 4-1 undergoes a reaction as shown in the following formula to obtain a compound as shown in Formula 4-2,
[0222] The organic base is potassium alkoxide and / or sodium alkoxide.
[0223] The conditions and operations of the preparation method of the compound represented by Formula 4-2 may be as described in any one of the present inventions.
[0224] The present invention provides a method for preparing a compound as shown in Formula 3, comprising the following steps S1: in a solvent, in the presence of an acid, the compound as shown in Formula 1 and the compound as shown in Formula 2 undergo a reaction as shown in the following formula to obtain a compound as shown in Formula 3,
[0225] The acid is one or more of methanesulfonic acid, trifluoroacetic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate.
[0226] The conditions and operations of the method for preparing the compound represented by Formula 3 may be as described in any one of the present inventions.
[0227] The present invention provides a compound as shown in Formula 7, 6-2, 5, 4, 4-3, 4-1, 3 or 1,
[0228] The present invention provides use of a compound represented by Formula 7 in the preparation of naloxone, nalbuphine, oxycodone or oxymorphone.
[0229] In the present invention, "room temperature" or "normal temperature" refers to 10-30°C, for example 25°C.
[0230] In the present invention, "ice water bath" or "ice salt bath" refers to -5-5°C, for example 0°C.
[0231] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0232] The reagents and raw materials used in the present invention are commercially available.
[0233] The positive progress of the present invention is that the intermediates provided by the present invention can be used to synthesize a variety of opioid derivatives and have one or more of the following advantages: cheap and readily available raw materials, simple synthesis steps and high product yields. DETAILED DESCRIPTION
[0234] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[0235] Example 1 Synthesis of the compound shown in Formula 1
[0236] The compound shown in formula 1-1:
[0237] To a clean 100L reactor, ethanol (75L), vanillin (10.0kg), methylamine hydrochloride (0.222kg), and triethylamine (0.333kg) were added sequentially at room temperature. The system formed a light cyan solution with a slight endotherm. After stirring for 5 minutes, nitromethane (4.41kg) was added, and the system immediately formed an orange-red solution. Stir vigorously for 1-2 hours, followed by gentle stirring for 16 hours. A large amount of solid precipitated. HPLC indicated complete consumption of the vanillin, indicating the reaction was complete. The reaction solution was filtered, and the filter cake was rinsed 1-2 times with 2L of ethanol. It was then dried in a 50°C oven for 24 hours to yield the final product (Compound I-1) as a dark yellow solid (10.3kg, 82% yield).
[0238] 1 H NMR (500MHz, CDCl3) δ7.96(d,J=13.3Hz,1H),7.52(d,J=13.5Hz,1H),7.14(d,J=7.7Hz,1H),7.04–6.94(m,2H),6.05(s,1H),3.96(s,3H).
[0239] 13 C NMR (126MHz, CDCl3) δ149.88,147.19,139.63,135.14,125.07,122.56,115.42,110.25,56.24.
[0240] HRMS(ESI+):194.0460.
[0241] The compound shown in formula 1
[0242] Under nitrogen, 60 L of tetrahydrofuran was added to a 100 L kettle. 2 kg (10.25 mol) of compound 1-1 was dissolved in 30 L of the mixture. 1.17 kg of solid granular lithium aluminum tetrahydride was then added to the kettle at 5°C and stirred for 5-10 minutes until a white suspension formed. The tetrahydrofuran solution of compound 1-1 was then pumped into the kettle, with the temperature maintained below 20°C. The system became a yellow or golden suspension, which was then heated to 30°C and stirred for 16 hours. After the reaction, the kettle temperature was lowered to 0°C, and 3.51 L of water was slowly added dropwise to quench the reaction, maintaining the kettle temperature below 20°C. The system became a light yellow suspension. After the addition was complete, the system was stirred for 30 minutes, followed by the addition of 2.46 kg (22.66 mol) of ethyl chloroformate at 0°C. The system remained a yellow suspension. After the addition was complete, the nitrogen was turned off, the temperature was allowed to rise naturally for 10 minutes, and the kettle temperature was raised to 25°C and stirred for 16 hours. After the reaction, water was added and stirred for 1-2 hours, and then filtered. The filtrate was washed once with 20 L of saturated brine and extracted with ethyl acetate (15 L). The organic phase was concentrated to obtain the product (Compound 1) (2.9 kg, 90% yield).
[0243] 1 H NMR (500MHz, CDCl3) δ7.04(d,J=8.0Hz,1H),6.82–6.71(m,2H),4.73(s,1H),4.30(q,J=7.1Hz,2H),4.10(dd,J=13.8 ,6.8Hz,2H),3.83(s,3H),3.42(d,J=6.2Hz,2H),2.79(t,J=6.6Hz,2H),1.37(t,J=7.1Hz,3H),1.22(t,J=6.9Hz,3H).
[0244] 13 C NMR (126MHz, CD3OD) δ156.7,153.5,151.2,138.8,138.1,122.5,120.9,113.1,65.0,60.9,56.0,42.1,36.2,14.7,14.3.
[0245] HRMS(ESI+):312.1447.
[0246] Example 2 Compound shown in Formula 2
[0247] The compound shown in formula 2-1
[0248] Dissolve isovanillin (10.0 g, 0.0657 mol, 1.0 eq.) in 100 mL of dichloromethane (DCM), cool to 0°C, and add N-bromosuccinimide (NBS) (12.8 g, 0.0723 mol, 1.1 eq.) in portions. Allow to react at 0°C for 1 hour before returning to room temperature for further reaction. After completion of the reaction, cool to 10°C, add saturated sodium chloride solution, stir for 0.5 hour, and filter. The filter cake is washed twice with water and dried to yield compound 2-1 (14.6 g, 96% yield). The organic phases from the filtrates can be combined and recrystallized from petroleum ether / ethyl acetate (1:1) to purify compound 2-1.
[0249] 1 H NMR (500MHz, CD3OD) δ10.20(s,1H),7.47(d,J=8.6Hz,1H),7.05(d,J=8.5Hz,1H),3.96(s,3H).
[0250] 13 C NMR (126MHz, CD3OD) δ191.20,153.23,127.05,121.49,113.22,109.36,55.52.
[0251] HRMS(ESI+):230.9642.
[0252] The compound shown in formula 2
[0253] Under nitrogen, toluene (50 L) was added to a 100-L autoclave with low stirring. Potassium tert-butoxide (5 kg, 44.6 mol, 2.5 eq.) was then added. The system was cooled to 0°C, and (methoxymethyl)triphenylphosphonium chloride (13.75 kg, 40.18 mol, 2.25 eq.) was added while maintaining the internal temperature below 5°C. The reaction was then heated to 25°C and allowed to react for 3 hours. The system was cooled to 0°C, and compound 2-1 (4.11 kg, 17.86 mol, 1.0 eq.) was slowly added. The reaction was then slowly warmed to room temperature and allowed to react for 16 hours. After the reaction, the system was cooled to 0°C and slowly quenched with water (20 L). KOH (500 g) was also added. The mixture was separated, the toluene phase removed, and the pH of the aqueous phase adjusted to a slightly acidic state with ammonium chloride. The system was extracted twice with ethyl acetate and concentrated to afford crude product 2 (4.28 kg, 93% yield) as a golden oil.
[0254] 1H NMR(500MHz,CDCl3)δ7.60(d,J=8.7Hz,1H),6.90–6.84(m,2H),6.77(dd,J=19.2,8.6Hz,2H),6.19(d,J=7.2Hz,1H),6 .02(d,J=12.8Hz,1H),5.95(d,J=16.6Hz,2H),5.54(d,J=7.2Hz,1H),3.89(d,J=3.3Hz,6H),3.76(s,3H),3.71(s,3H).
[0255] Example 3 Compound shown in Formula 3
[0256] In a clean, dry round-bottom flask equipped with a stirrer, compound 1 (36.4 g, 0.117 mol, 1.0 equiv), compound 2 (42.3 g, 0.164 mol, 1.4 equiv), and dichloromethane (150 mL) were added. Then, p-toluenesulfonic acid monohydrate (45.7 g, 0.24 mol, 2.0 equiv) was added at room temperature and stirred for 16 h. After the reaction was completed, water was added to quench the reaction. The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain the crude product. The crude product was recrystallized from a mixture of ethyl acetate and petroleum ether (2:1) to obtain product 3 (50.2 g, 80% yield).
[0257] 1H NMR (500MHz, CDCl3) δ7.08(s,1H),6.77(s,1H),6.71(d,J=5.4Hz,2H),6.68(d,J=3.0Hz,1H),6.61(d,J=8.3Hz,1H),6.56(d,J=8.2Hz,1H) ,6.02(s,1H),5.96–5.89(m,1H),5.45–5.39(m,1H),4.40–4.26(m,4H),4.07–4.02(m,1H),4.00–3.95(m,1H),3.87(s,3H),3.86(s,1H),3 .83(s,3H),3.82(s,1H),3.75(dt,J=10.4,7.2Hz,1H),3.57–3.48(m,1H),3.41(s,1H),3.33–3.20(m,2H),3.19–3.09(m,1H),2.93(dt,J= 11.7,8.8Hz,2H),2.85–2.80(m,1H),2.72(d,J=15.1Hz,1H),2.68(s,1H),1.43–1.34(m,4H),1.19(d,J=7.1Hz,1H),0.92(t,J=7.1Hz,3H).
[0258] 13 C NMR (126MHz, CDCl3) δ155.6,153.5,149.9,145.9,143.1,138.5,133.1,130.6,129.1,122. 0,120.8,112.7,111.5,109.4,65.1,61.3,56.5,56.1,53.2,42.2,36.6,28.8,14.3,14.1.
[0259] HRMS(ESI+):560.0895
[0260] Example 4 Compound shown in Formula 4
[0261] The compound shown in formula 4-1
[0262] Under a nitrogen atmosphere, a clean, dry 100-L reactor was charged with N,N-dimethylformamide (DMF) (20 L) and stirred at low speed. Compound 3 (7.8 kg, 12.4 mol, 1.0 equiv) was then added. Potassium carbonate (2.78 kg, 24.8 mol, 2.0 equiv) and benzyl bromide (1.39 kg, 24.8 mol, 2.0 equiv) were then added sequentially at room temperature. The reaction was allowed to proceed at room temperature for 6 hours. After completion of the reaction, water (40 L) was added to the system to precipitate the solid product, which was filtered to obtain a brown solid. This brown solid was directly dissolved in ethanol (20 L), followed by the addition of 20 g of solid KOH (2.0 equiv). The system was heated to 50°C and stirred for 3 hours. After completion of the reaction, the system was cooled to room temperature, water (40 L) was added, and the mixture was stirred for 2 hours. The system was filtered, and the filter cake was slurried with methanol, filtered again, and dried to obtain the gray solid product 4-1 (8.0 kg).
[0263] Compounds such as those shown in formula 4-2
[0264] Under a nitrogen atmosphere, tetrahydrofuran (40 L) was added to a clean, dry 100 L reactor with low stirring. Compound 4-1 (7.8 kg, 12.4 mol, 1.0 equiv) was then added. Potassium tert-butoxide (2.78 kg, 24.8 mol, 2.0 equiv) and potassium hydroxide (1.39 kg, 24.8 mol, 2.0 equiv) were then added at room temperature. The reaction was heated to 70°C for 8 hours. After completion of the reaction, the system was cooled to 10°C and quenched with water (15 L). The system was extracted with dichloromethane three times (15 L x 3). The solvent was evaporated to afford crude product 4-2 (5.85 kg) as a pale yellow foamy solid.
[0265] Compounds shown in formula 4-3
[0266] Crude compound 4-2 (5.85 kg, 12.4 mol, 1.0 equiv) and methanol (20 L) were added to a clean, dry 100-L reactor. D-(+)-di-p-methylbenzoyltartaric acid ((+)-DTTA) (5.0 kg, 13.0 mol, 1.05 equiv) was then added at room temperature. The reaction was heated to 85°C for 8 hours. After completion of the reaction, product 4-3 (3.2 kg, 95% ee) was obtained by direct filtration as a white solid (Chiral HPLC conditions: OD-H, i-PrOH / hexane = 80:20, flow rate 1.0 mL / min, 210 nm, t = 6.5 min, t = 8.0 min, T = 15.00 min).
[0267] The compound shown in formula 4
[0268] A clean 50-L reactor was charged with dichloromethane (30 L) and compound 4-3 (3.2 kg, 3.79 mol, 1.0 equiv). An aqueous solution of potassium bicarbonate (KHCO₃) (1.9 kg, 19 mol, 5.0 equiv) was added with stirring. The system was stirred at room temperature for 1 hour. The dichloromethane phase was collected, and the aqueous phase was extracted twice with dichloromethane (5 L x 2). The combined dichloromethane phases were transferred to another clean reactor. The system was cooled to 20°C, and di-tert-butyl carbonic anhydride (Boc₂O) (871 g, 4.0 mol, 1.08 equiv) was added. The reaction was maintained at room temperature for 3 hours. After the reaction, most of the dichloromethane was evaporated and replaced with methanol. The precipitated solid was filtered and dried to obtain product 4 (2.07 kg, 96% yield) as a white sand.
[0269] 1 H NMR (400MHz, CDCl3) δ7.59 (d, J = 7.2Hz, 2H), 7.40 (t, J = 7.4Hz, 2H), 7.34 (t, J = 7. 3Hz,1H),6.97(s,1H),6.81(s,2H),6.61(s,1H),5.59(s,1H),5.32(dd,J=11.0,2 .9Hz,1H),5.05(s,2H),4.38(dd,J=13.3,5.2Hz,1H),3.88(s,3H),3.84(s,3H), 3.29–3.23(m,2H),2.97–2.88(m,2H),2.64(dd,J=16.1,2.0Hz,1H),1.11(s,9H).
[0270] 13 C NMR (101MHz, CDCl3) δ154.6,152.7,145.6,145.4,144.1,137.4,131.3,130.1,128.5,128.4,128.1,126 .5,125.9,121.4,112.8,111.3,110.9,79.5,74.7,56.3,56.1,53.7,42.3,36.2,28.5,28.5,28.1,27.8.
[0271] HRMS(ESI+):584.1652.
[0272] Example 5 Compound shown in Formula 5
[0273] To a clean, dry 250 mL Shrek tube was added palladium chloride (60 mg, 0.34 mmol), di(1-adamantyl)-n-butylphosphine (168 mg, 0.52 mmol), potassium carbonate (2.37 g, 17.2 mmol), and compound 4 (5 g, 8.6 mmol). The atmosphere was purged with nitrogen three times, followed by the addition of N,N-dimethylacetamide (30 mL). The reaction was stirred at 140°C for 6 hours. After completion of the reaction, the system was cooled to room temperature, and dichloromethane (100 mL) was added. The crude product was filtered through celite, concentrated, and purified by column chromatography (eluent: dichloromethane / methanol mixture (150:1 to 100:1)) to afford compound 5 as a yellow solid (2.3 g, 53% yield).
[0274] 1 H NMR (400MHz, CDCl3) δ7.50(d,J=6.9Hz,2H),7.41(t,J=7.3Hz,2H),7.35(t,J=7.0Hz,1H),6.88(s,2H),6.31(d,J=20.1Hz,1H),5.33(d,J=11.1Hz,1H) ,5.15–4.89(m,2H),3.96–3.77(m,4H),3.40(s,3H),3.16(tt,J=29.0,14.5 Hz,2H),2.87–2.70(m,1H),2.34(d,J=12.4Hz,1H),1.47(d,J=29.0Hz,9H).
[0275] 13 C NMR (101MHz, CDCl3) δ181.1,159.8,154.7,152.0,151.6,146.4,137.5,130.9,128.8,128.2,127.4,127.3,124.5,12 2.0,121.8,120.3,120.1,112.3,80.6,80.5,74.3,56.1,54.9,54.0,52.8,44.1,39.5,39.0,38.9,38.8,29.8,28.5.
[0276] HRMS(ESI+):504.2388.
[0277] Example 6 Compound shown in Formula 6
[0278] The compound shown in formula 6-1
[0279] Under nitrogen, palladium chloride (1.76 g, 10 mmol) and sodium hydride (12 g, 0.3 mol, 60% in mineral oil) were added to a clean, dry 1L three-necked round-bottom flask and stirred for 30 minutes. The system was cooled to 0°C, and then a solution of 5 (100 g, 0.2 mol) in N,N-dimethylacetamide (DMAc) (500 mL) was added. The entire reaction system was allowed to warm to 25°C and stirred for 10 hours. After completion of the reaction, the system was cooled to 0°C and quenched by the addition of water (200 mL). The crude product was extracted three times with ethyl acetate (300 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to afford crude product 6-1 (80 g) as a brown oil.
[0280] Compounds such as those shown in Formula 6-2
[0281] Under nitrogen, crude compound 6-1 (80 g, 0.19 mol, 1.0 equiv) and tetrahydrofuran (600 mL) were added to a clean, dry 1L, three-necked round-bottom flask. The system was cooled to -20°C, and a solution of diisobutylaluminum hydride (DIBAL-H) in tetrahydrofuran (THF) (258 mL, 0.39 mol, 2.0 equiv) was slowly added while maintaining the internal temperature below 5°C. After the addition was complete, the reaction system was warmed to 15°C and reacted for 30 minutes. After the reaction, the system was poured into cooled aqueous NaOH (4N) to quench the reaction. The system was extracted with dichloromethane five times (500 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to afford crude product 6-2 (75.4 g) as a brown oil.
[0282] The compound shown in Formula 6
[0283] Under a nitrogen atmosphere, compound 6-2 (75.4 g, 0.18 mol, 1.0 equiv) was added to a clean, dry round-bottom flask, followed by dichloromethane (200 mL). N,N-dimethylformamide dimethyl acetal (DMFDMA) (35.6 mL, 0.27 mol, 1.5 equiv) was then added at room temperature. The reaction was allowed to proceed for 3 hours. After completion of the reaction, the system was directly concentrated and extracted three times with a mixture of petroleum ether and ethyl acetate (6:1). The organic phases were combined and dried by spin drying. Product 6 (27.6 g, 35% yield) was then precipitated in methanol / water (4:1) at -10°C.
[0284] 1H NMR (500MHz, CDCl3) δ6.68–6.63(m,1H),6.57(d,J=8.1Hz,1H),5.57(d,J=2 4.6Hz,1H),5.27(d,J=4.3Hz,1H),5.18–4.95(m,2H),4.01(dd,J=60.2,13. 4Hz,1H),3.87–3.80(m,3H),3.62–3.54(m,3H),3.27–3.04(m,2H),2.97(d, J=18.0Hz,1H),2.03(d,J=12.0Hz,1H),1.76(s,1H),1.47(d,J=11.0Hz,9H).
[0285] 13 C NMR (126MHz, CDCl3) δ154.4, 152.9 (d, J = 26.2Hz), 144.9, 143.1, 132.6, 130.5 (d, J = 29.1Hz), 126.7 (d, J = 23.7Hz), 119.6 ,113.2(d,J=10.9Hz).111.8,111.5,95.9,95.7,88.9,79.9,56.4,55.1,53.2,51.7,46.4,38.2,37.9,37.3,36.9,28.5.
[0286] HRMS(ESI+):398.1970.
[0287] Example 7 Compound shown in Formula 7
[0288] A clean, dry round-bottom flask was charged with compound 6 (10 g, 25.2 mmol, 1.0 equiv) and a 7:2:1 dichloromethane / acetic acid / water mixture (200 mL). The mixture was cooled to 0°C and magnesium monoperoxyphthalate hexahydrate (MMPP) (14.6 g, 37.8 mmol, 1.5 equiv) was added. The temperature was raised to 15°C and the reaction was allowed to react for 3 hours. After completion of the reaction, the reaction was quenched with aqueous sodium thiosulfate and extracted three times with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (eluent: a 4:1 dichloromethane / ethyl acetate mixture) to afford product 7 (8.94 g, 89% yield) as a yellow foamy solid.
[0289] Optical rotation [α] D 25 =-164.3°(c 1.0CHCl3).
[0290] 1 H NMR (500MHz, CDCl3) δ6.75–6.69(m,2H),6.63(d,J=8.2Hz,1H),6.16(d,J=10.1Hz,1H),4.72(s ,2H),3.97(s,1H),3.85(s,3H),2.98(d,J=3.4Hz,2H),2.84(s,1H),2.46(s,1H),1.50(s,9H).
[0291] 13 C NMR (126MHz, CDCl3) δ194.4,144.4,143.0,133.7,130.1,124.3,120.1,119.7,115.3, 111.6,109.2,86.8,80.9,68.1,63.6,56.8,56.3,54.4,47.3,31.6,29.7,28.5,27.6.
[0292] HRMS(ESI+):400.1766.
[0293] Example 8 Compound shown in Formula 8
[0294] The compound shown in formula 8-1
[0295] Compound 7 (500 mg, 1.25 mmol) and palladium on carbon (50 mg, 10% Pd on carbon) were added to a clean, dry 50 mL round-bottom flask, followed by methanol (10 mL). The entire system was placed in an autoclave and the hydrogen atmosphere was replaced three times to a hydrogen pressure of 2 atm. The reaction was continued at 30°C for 4 hours. After completion of the reaction, the palladium on carbon was recovered by filtration over celite, and the filtrate was directly concentrated to yield the crude product 8-1 (500 mg) as a pale green foam.
[0296] 1 H NMR (500MHz, CDCl3) δ6.74(d,J=8.2Hz,1H),6.65(d,J=8.0Hz,1H),4.67(s,1H),4.52(s,1H),3.90(d,J=2.2Hz,3H),3.11–2.96(m,2H), 2.90(d,J=18.2Hz,1H),2.72(s,2H),2.41(s,1H),2.30(d,J=14.3Hz,1H),1.92(d,J=12.1Hz,1H),1.66(d,J=13.1Hz,2H),1.50(s,9H).
[0297] Compounds such as those shown in formula 8-2
[0298] Crude compound 8-1 (450 mg, 1.12 mmol) and methanol (10 mL) were added to a clean three-necked flask. The system was cooled to 0°C and a methanolic solution of HCl (4N, 12 mL) was slowly added, maintaining the temperature below 10°C. After completion of the reaction (~1.5 h), the system was concentrated at 30°C to afford crude product 8-2 (410 mg) as a pale yellow solid.
[0299] 1 H NMR(500MHz,DMSO-d6)δ9.66(d,J=10.8Hz,1H),8.54(s,1H),6.84(d,J=8.2 Hz,1H),6.76(d,J=8.2Hz,1H),6.54(s,1H),5.00(s,1H),3.80(s,3H),3.70( s,1H),3.31(d,J=19.2Hz,1H),3.20(d,J=29.8Hz,1H),3.14–2.89(m,3H),2. 10(d,J=14.4Hz,1H), 1.95(d,J=13.2Hz,1H), 1.43(dd,J=21.5,11.7Hz,2H).
[0300] The compound shown in formula 8
[0301] In a clean and dry Shrek tube, crude compound 8-2 (380 mg, 1.12 mmol) was added, nitrogen was replaced three times, N-methylpyrrolidone and 6 mL of water (NMP:H2O=5:1) were added, triethylamine (0.78 mL, 5.6 mmol) was added at room temperature, stirred for 5 minutes, and then cyclopropylmethyl bromide (0.14 mL, 1.5 mmol) was added. The whole system was reacted at 70°C for 4 h. After the reaction was completed, it was cooled to room temperature and water (15 mL) was added. The system was extracted three times with dichloromethane (20 mL×3), the organic phase was dried and concentrated, and purified by column chromatography (eluent was a mixed solvent of dichloromethane / methanol=50:1) to give a white solid compound 8 (286 mg, 72% yield).
[0302] 1H NMR (500MHz, CDCl3) δ6.68(d,J=8.1Hz,1H),6.60(d,J=8.1Hz,1H),4.68(s, 1H),3.87(s,3H),3.29(s,1H),3.03(t,J=14.5Hz,2H),2.75(s,2H),2.61(d, J=15.6Hz,1H),2.46(s,3H),2.28(d,J=14.3Hz,1H),2.21–2.09(m,1H),1.91 (s,1H),1.67–1.51(m,2H),0.90(s,1H),0.56(d,J=6.8Hz,2H),0.17(s,2H).
[0303] 13 C NMR (101MHz, CDCl3) δ208.53,145.15,143.07,129.63,124.94,119.49,115.18,90.50,70.2 7,62.21,59.32,57.00,50.88,43.81,36.26,31.62,30.74,29.78,22.80,9.43,4.11,3.94.
[0304] HRMS(ESI+):356.1860.
[0305] Example 9 Compound represented by Formula 9 (Naltrexone)
[0306] Compound 8 (80 mg, 0.225 mmol) was added to a clean, dry Shrek tube. The atmosphere was purged with nitrogen three times and dry dichloromethane (5 mL) was added. The reaction mixture was cooled to -10°C, followed by the slow dropwise addition of boron tribromide (0.15 mL, 1.6 mmol). The temperature was raised to 10°C and stirred for 2 hours. After the reaction, the reaction mixture was cooled to 0°C and saturated ammonium chloride (5 mL) was added. The pH was then adjusted to 8 by the addition of saturated 10% NaHCO₃. The mixture was extracted four times with dichloromethane (20 mL x 4). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (eluent: dichloromethane / methanol = 50:1) to afford naltrexone (58 mg, 76% yield) as a white solid.
[0307] 1H NMR (500MHz, CDCl3) δ6.72 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 7.9 Hz, 1H), 4.69 (s, 1H), 3.20 (d, J = 4. 8Hz,1H),3.11–2.98(m,2H),2.71(d,J=7.7Hz,1H),2.57(dd,J=18.3,5.5Hz,1H),2.49–2.37(m ,3H),2.32(d,J=14.4Hz,1H),2.17(dd,J=12.1,9.1Hz,1H),1.89(d,J=13.1Hz,1H),1.62(ddd, J=27.4,19.5,6.8Hz,2H),0.87(d,J=6.9Hz,1H),0.55(d,J=7.6Hz,2H),0.15(d,J=4.5Hz,2H).
[0308] 13 C NMR (126MHz, CDCl3) δ210.13,143.60,138.95,129.11,124.34,120.07,118.09,90.72,7 0.38,62.17,59.35,51.18,43.76,36.33,31.51,30.77,29.84,22.78,9.52,4.15,3.96.
[0309] HRMS(ESI+):m / z calculated for C 20 H 24 NO4[M+H] + :342.1700,found:342.1703.
[0310] Comparative Example 1:
[0311] The same steps as those for synthesizing compound 4 were used. A potassium bicarbonate (KHCO3) aqueous solution was added to a dichloromethane solution of compound 4-3. After stirring for 1 hour, the dichloromethane phase was separated and ethyl chloroformate (ClCOOEt) (1.05 equiv) was added. After the reaction was completed, water was added to quench the reaction and the liquids were separated. The organic phase was dried and spin-dried, and separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1:1) to obtain compound 4a.
[0312] 1H NMR (500MHz, CDCl3) δ7.58 (dd, J=16.2, 7.3Hz, 2H), 7.37 (ddd, J=29.4, 13.9, 6.9Hz, 3H), 6.92 (s, 1H), 6. 78(d,J=8.1Hz,2H),6.63–6.55(m,1H),5.50(d,J=46.1Hz,1H),5.41–5.34(m,1H),5.00(d,J=23.7Hz,2H) ,4.35(dd,J=13.0,4.9Hz,1H),4.05(dd,J=7.1,3.4Hz,1H),3.94–3.80(m,6H),3.80–3.74(m,1H),3.56–3 .38(m,1H),3.34–3.09(m,2H),3.00–2.74(m,2H),2.64(t,J=17.3Hz,1H),1.06(dt,J=125.0,7.1Hz,3H).
[0313] Following the same steps as for the synthesis of compound 5, palladium chloride (60 mg, 0.34 mmol), di(1-adamantyl)-n-butylphosphine (168 mg, 0.52 mmol), potassium carbonate (2.37 g, 17.2 mmol), and compound 4a (4.75 g, 8.6 mmol) were added to a clean, dry 250 mL three-necked flask. The system was purged with nitrogen three times, followed by the addition of N,N-dimethylacetamide (30 mL). The reaction system was stirred at 140°C for 6 hours. After completion of the reaction, the system was cooled to room temperature, and dichloromethane (100 mL) was added. The crude product was filtered through celite, concentrated, and purified by column chromatography (eluent: dichloromethane / methanol mixture (150:1 to 100:1)) to afford compound 5a as a yellow solid (2.2 g, 55% yield).
[0314] 1H NMR (500MHz, CDCl3) δ7.41(d,J=8.6Hz,2H),7.30(s,1H),6.93(d,J=8.6Hz,2H),6.87(s,2H),6. 30(d,J=15.8Hz,1H),5.29(s,2H),5.14(s,1H),5.01(s,1H),4.96(d,J=10.8Hz,1H),4.24–4.09( m,2H),3.89(s,3H),3.83(s,3H),3.46(s,3H),3.25–3.06(m,2H),2.91(d,J=36.1Hz,1H),2.82(s ,1H),2.34(dd,J=13.0,2.3Hz,1H),1.59–1.50(m,1H),1.32(t,J=6.9Hz,1H),1.27–1.21(m,2H).
[0315] As with the synthesis of compound 6, compound 6a can be obtained starting from compound 5a under the same conditions.
[0316] 1 H NMR (500MHz, CDCl3) δ6.68 (d, J = 8.2 Hz, 1H), 6.60 (d, J = 8.1 Hz, 1H), 5.61 (dd, J = 20. 7,6.1Hz,1H),5.14(dd,J=71.3,6.4Hz,1H),5.04(d,J=6.4Hz,1H),4.24–4.00(m,4 H),3.85(s,3H),3.70(s,1H),3.60(s,3H),3.32–3.08(m,2H),3.05–2.98(m,1H),2 .08(dt,J=12.5,6.1Hz,1H),1.81(t,J=12.1Hz,1H),1.27(dd,J=16.1,8.9Hz,4H).
[0317] When synthesizing naltrexone from compound 6a, the inventors tried numerous conditions but were unsuccessful due to the inability to remove the -COOEt protecting group. Using the -COOEt removing conditions described in Example 4 for the preparation of the compound represented by Formula 4-2 resulted in unstable scaffolds in compound 6a, resulting in numerous byproducts and a very low yield of the target compound.
[0318] The inventors also tried to remove the protecting group under acidic and other alkaline conditions, which also caused the skeleton to be unstable, resulting in almost no target product or extremely low yield.
[0319] It can be seen from the above comparative examples that using tert-butyloxycarbonyl (Boc) as a protecting group is not only easy to remove under acidic conditions and stabilizes the skeleton, thereby increasing the yield of the target product, but also facilitates subsequent functional group transformation.
Claims
1. A method for preparing a compound as shown in formula A8, characterized in that: It includes the following steps S11, S12 and S13: S11: In a solvent, in the presence of a catalyst, the compound represented by Formula 7 is subjected to a hydrogenation reaction represented by the following formula with hydrogen to obtain a compound represented by Formula 8-1, S12: In a solvent, in the presence of a deprotection agent, the compound represented by Formula 8-1 undergoes a deprotection reaction represented by the following formula to obtain a compound represented by Formula 8-2, S13: In a solvent, in the presence of a base, the compound represented by Formula 8-2 and the compound represented by Formula SM1 undergo a substitution reaction as shown in the following formula to obtain a compound represented by Formula A8, Where X is a halogen, R 1 C 1-4 Alkyl or one or more R 1-1 Substituted C 1-4 Alkyl; R 1-1 is a 3-6 membered cycloalkyl or C 2- 4-Alkenyl.
2. The method for preparing the compound of formula A8 according to claim 1, characterized in that: It meets one or more of the following conditions: (1) In X, the halogen is F, Cl, Br or I, such as Br; (2) R 1 In the C 1-4 Alkyl and the one or more R 1-1 Substituted C 1-4 C in the alkyl group 1-4 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl or isobutyl, for example methyl; (3) R 1 In the above, the one or more R 1-1 Substituted C 1-4 Alkyl is an R 1-1 Substituted C 1-4 alkyl; (4) R 1-1 wherein the 3-6 membered cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, such as cyclopropyl or cyclobutyl; and (5) R 1-1 In the C 2-4 Alkenyl is ethenyl, propenyl or butenyl, for example ethenyl.
3. The method for preparing the compound as shown in formula A8 according to claim 2, characterized in that: It meets one or both of the following conditions: (1) X is Br; and (2)R 1 Methyl, For example 4. The method for preparing the compound as shown in formula A8 according to any one of claims 1 to 3, characterized in that: It meets one or more of the following conditions: (1) In step S11, the solvent is an alcohol solvent, such as methanol and / or ethanol; another example is methanol; (2) In step S11, the molar volume ratio of the compound represented by Formula 7 to the solvent is (0.1-0.3) mol:1L, for example, 0.13 mol:1L; (3) In step S11, the catalyst is a Raney nickel and / or palladium catalyst, such as a palladium catalyst, and another example is 10% palladium / carbon, where "%" is the mass percentage of palladium to the total mass of palladium and carbon; (4) In step S11, the mass ratio of the catalyst to the compound represented by formula 7 is (0.01-1):1, for example (0.05-0.5):1, and for example 0.1:1; (5) In step S11, the pressure of the hydrogenation reaction is 1-10 atm, for example, 1-3 atm, and another example is 2 atm; (6) In step S11, the temperature of the hydrogenation reaction is 10-45°C, for example, 20-30°C, and for example, 30°C; (7) In step S11, the hydrogenation reaction time is 1-10 h, for example 3-6 h, and for example 4 h; (8) In step S11, after the hydrogenation reaction is completed, the following post-processing steps are also included: filtration and concentration; (9) In step S11, after the hydrogenation reaction is completed, the next step of reaction is directly carried out without purification; (10) In step S12, the solvent is an alcohol solvent, such as methanol and / or ethanol; another example is methanol; (11) In step S12, the molar volume ratio of the compound represented by formula 8-1 to the solvent is (0.01-1) mol:1L, for example, 0.05 mol:1L; (12) In step S12, the deprotection reagent is an acid, such as an inorganic acid, or hydrochloric acid; or a 4 mol / L methanol solution of hydrochloric acid; (13) In step S12, the molar ratio of the acid to the compound represented by formula 8-1 is (1-100):1, for example (30-60):1, and for example 43:1; (14) In step S12, the temperature of the deprotection reaction is 0-20°C, for example, 10°C; (15) In step S12, the deprotection reaction time is 0.5-3 h, for example 1.5 h; (16) In step S12, after the deprotection reaction is completed, the following post-treatment steps are also included: concentration; (17) In step S12, after the deprotection reaction is completed, the next step reaction is directly carried out without purification; (18) The compound represented by formula SM1 is The compound shown in formula A8 is (19) In step S13, the solvent is a mixed solvent of an organic solvent and water; the organic solvent may be a pyrrolidone organic solvent, such as N-methylpyrrolidone; the volume ratio of the organic solvent to water may be (1-10):1, such as (4-6):1, and another example is 5:1; (20) In step S13, the molar volume ratio of the compound represented by formula 8-2 to the solvent is (0.01-0.3) mol:1L, for example, 0.19 mol:1L; (21) In step S13, the base is an organic base, such as an organic amine, and another example is triethylamine; (22) In step S13, the molar ratio of the base to the compound represented by formula 8-2 is (1-10):1, for example (4-6):1, and for example 5:1; (23) In step S13, the molar ratio of the compound represented by formula SM1 to the compound represented by formula 8-2 is (1-3):1, for example (1-1.5):1, and for example 1.3:1; (24) In step S13, the substitution reaction is carried out under the protection of an inert gas, and the inert gas may be nitrogen and / or argon, such as nitrogen; (25) In step S13, the temperature of the substitution reaction is 60-90° C., for example, 70° C.; (26) In step S13, the substitution reaction time is 1-6 hours, for example 4 hours; and (27) In step S13, after the substitution reaction is completed, the following post-treatment steps are also included: one or more of extraction, drying, concentration and purification; the extraction solvent may be dichloromethane; the drying desiccant may be anhydrous sodium sulfate; the concentration may be reduced pressure distillation; the purification may be column chromatography; the eluent of the column chromatography may be a mixed solvent of dichloromethane and methanol, for example, the volume ratio of dichloromethane to methanol is 50:
1.
5. The method for preparing the compound as shown in formula A8 according to claim 1, characterized in that: The method for preparing the compound shown in Formula A8 also includes a method for preparing the compound shown in Formula 7, which specifically includes the following steps S10: in a solvent, in the presence of an oxidant, the compound shown in Formula 6 undergoes an oxidation reaction as shown in the following formula to obtain a compound shown in Formula 7, 6. The method for preparing the compound of formula A8 as claimed in claim 5, characterized in that: It meets one or more of the following conditions: (1) In step S10, the solvent is one or more of an organic acid solvent, a chlorinated alkane solvent and water, for example, a mixed solvent of an organic acid solvent, a chlorinated alkane solvent and water; The chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; The organic acid solvent may be formic acid and / or acetic acid, such as acetic acid; In the mixed solvent, the volume ratio of the chlorinated alkane solvent to water may be (1-10):1, for example 7:1; In the mixed solvent, the volume ratio of the organic acid solvent to water may be (1-10):1, for example, 2:1; (2) In step S10, the molar volume ratio of the compound represented by Formula 6 to the solvent is (0.01-1) mol:1L; for example, (0.01-0.3) mol:1mL, and another example is 0.13 mol:1L; (3) the oxidant is selected from one or more of hydrogen peroxide, m-chloroperbenzoic acid and magnesium monoperoxyphthalate hexahydrate, such as magnesium monoperoxyphthalate hexahydrate; (4) In step S10, the molar ratio of the oxidant to the compound represented by Formula 6 is (1-5):1, for example (1.1-2):1, and for example 1.5:1; (5) In step S10, the temperature of the oxidation reaction is -20°C-25°C, for example, 0°C-20°C, and for example, 15°C; (6) In step S10, the oxidation reaction further comprises the following steps: mixing the compound as shown in Formula 6 and the solvent, and adding the oxidant; the oxidant may be added at -5-5°C, for example, at 0°C; (7) In step S10, the oxidation reaction time is 1-5 hours, for example 3 hours; and (8) In step S10, after the oxidation reaction is completed, the following post-treatment steps are further included: one or more of quenching, extraction, drying, concentration and purification; the quenching solvent may be an aqueous sodium thiosulfate solution; the extraction solvent may be dichloromethane; the drying desiccant may be anhydrous sodium sulfate; the concentration may be reduced pressure distillation; the purification may be column chromatography, and the eluent of the column chromatography may be a mixed solvent of dichloromethane and ethyl acetate, for example, the volume ratio of dichloromethane to ethyl acetate is 4:
1.
7. The method for preparing the compound of formula A8 as claimed in claim 5, characterized in that: The method for preparing the compound shown in Formula 7 also includes the method for preparing the compound shown in Formula 6, which specifically includes the following steps S9: in a solvent, in the presence of a cyclization reagent, the compound shown in Formula 6-2 undergoes a cyclization reaction as shown in the following formula to obtain the compound shown in Formula 6, 8. The method for preparing the compound of formula A8 according to claim 7, characterized in that: It meets one or more of the following conditions: (1) In step S9, the cyclization reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, for example, nitrogen; (2) In step S9, the solvent is a chlorinated alkane solvent; the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; (3) In step S9, the molar volume ratio of the compound represented by formula 6-2 to the solvent is (0.1-2) mol:1L, for example 0.9 mol:1L; (4) In step S9, the cyclization reagent is N,N-dimethylformamide dimethyl acetal, p-toluic acid, sodium methoxide and ethanol. Sodium, for example, N,N-dimethylformamide dimethyl acetal; (5) In step S9, the molar ratio of the cyclization reagent to the compound of formula 6-2 is (1-5):1, for example (1-3):1, and for example 1.5:1; (6) In step S9, the temperature of the cyclization reaction is 20-35°C, for example, 25°C; (7) In step S9, the cyclization reaction time is 1-5 hours, for example 3 hours; and (8) In step S9, after the cyclization reaction is completed, the following post-treatment steps are also included: one or more of extraction, drying, concentration and purification; the extraction solvent can be a mixed solvent of petroleum ether and ethyl acetate, for example, the volume ratio of petroleum ether to ethyl acetate is 6:1; the drying desiccant can be anhydrous sodium sulfate; the concentration can be reduced pressure distillation; the purification can be crystallization; the crystallization solvent can be a mixed solvent of methanol and water, for example, the volume ratio of methanol to water is 4:1; the crystallization temperature can be -20-0°C, for example, -10°C.
9. The method for preparing the compound of formula A8 according to claim 7, characterized in that: The method for preparing the compound shown in Formula 6 also includes a method for preparing the compound shown in Formula 6-2, which specifically includes the following step S8: in a solvent, in the presence of a reducing agent, the compound shown in Formula 6-1 is subjected to a reduction reaction as shown in the following formula to obtain a compound shown in Formula 6-2, 10. The method for preparing the compound of formula A8 according to claim 9, characterized in that: It meets one or more of the following conditions: (1) In step S8, the reduction reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, for example, nitrogen; (2) In step S8, the solvent is an ether solvent, such as tetrahydrofuran; (3) In step S8, the molar volume ratio of the compound represented by formula 6-1 to the solvent is (0.1-2) mol:1L, for example, 0.22 mol:1L; (4) In step S8, the reducing agent is selected from one or more of alkali metal borohydride, lithium aluminum hydride and diisobutylaluminum hydride, such as diisobutylaluminum hydride, and another example is a tetrahydrofuran solution of diisobutylaluminum hydride; (5) In step S8, the molar ratio of the reducing agent to the compound represented by Formula 6-1 is (1-5):1, for example (1-3):1, and for example 2:1; (6) In step S8, the temperature of the reduction reaction is -5-35°C, for example, 10-30°C, and for example, 15°C; (7) In step S8, the reduction reaction time is 0.1-2 h, for example 0.5 h; (8) Step S8 further includes the following steps: mixing the compound represented by Formula 6-1 with the solvent and then adding the reducing agent to carry out the reduction reaction; the reducing agent can be added at -25-5°C, for example, at -20°C or 5°C; and (9) In step S8, after the reduction reaction is completed, the following post-treatment steps are also included: one or more of quenching, extraction, drying and concentration; the quenching solvent can be an aqueous sodium hydroxide solution, such as an aqueous sodium hydroxide solution with a molar concentration of 4N; the extraction solvent can be dichloromethane; the drying desiccant can be anhydrous sodium sulfate; and the concentration can be reduced pressure distillation.
11. The method for preparing the compound of formula A8 according to claim 9, characterized in that: The method for preparing the compound shown in Formula 6-2 also includes the method for preparing the compound shown in Formula 6-1, which specifically includes the following step S7: in a solvent, in the presence of a hydrogen source and a palladium catalyst, the compound shown in Formula 5 is subjected to a debenzylation protection reaction as shown in the following formula to obtain the compound shown in Formula 6-1, 12. The method for preparing the compound of formula A8 according to claim 11, characterized in that: It meets one or more of the following conditions: (1) In step S7, the debenzylation reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, such as nitrogen; (2) In step S7, the solvent is an ether solvent or an amide solvent, such as an amide solvent, and another example is N,N-dimethylacetamide; (3) In step S7, the molar volume ratio of the compound represented by Formula 5 to the solvent is (0.1-1) mol:1L, for example, 0.4 mol:1L; (4) In step S7, the hydrogen source is hydrogen gas and / or sodium hydride, such as sodium hydride; (5) In step S7, the molar ratio of the hydrogen source to the compound represented by Formula 5 is (1-2):1, for example, 1.5:1; (6) In step S7, the palladium catalyst is selected from one or more of dry palladium carbon, palladium hydroxide, palladium chloride and palladium acetate, such as palladium chloride; (7) In step S7, the molar ratio of the palladium catalyst to the compound represented by Formula 5 is (0.01-0.5):1, for example 0.05:1; (8) In step S7, the temperature of the debenzylation reaction is 10-30° C., for example, 25° C.; (9) In step S7, the reaction time of the debenzylation protection is 1-20 hours, for example 10 hours; and (10) In step S7, after the debenzylation reaction is completed, the following post-treatment steps are further included: one or more of quenching, extraction, drying and concentration; the quenching solvent may be water; the extraction solvent may be ethyl acetate; the drying desiccant may be anhydrous sodium sulfate; and the concentration may be reduced pressure distillation.
13. The method for preparing the compound of formula A8 according to claim 11, characterized in that: The preparation method of the compound shown in Formula 6-1 also includes the preparation method of the compound shown in Formula 5, which specifically includes the following step S6: in a solvent, under the action of a palladium catalyst, a phosphine ligand and a base, the compound shown in Formula 4 undergoes a dearomatization cyclization reaction as shown in the following formula to obtain a compound shown in Formula 5, 14. The method for preparing the compound represented by formula A8 according to claim 13, characterized in that: It meets one or more of the following conditions: (1) In step S6, the dearomatization cyclization reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, such as nitrogen; (2) In step S6, the solvent is a sulfoxide solvent and / or an amide solvent, such as an amide solvent; the amide solvent may be one or more of N-pyrrolidone, N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA), such as N,N-dimethylacetamide; (3) In step S6, the molar volume ratio of the compound represented by formula 4 to the solvent is (0.01-1) mol:1L, for example, 0.29 mol:1L; (4) In step S6, the palladium catalyst is one or more of palladium chloride, bis(acetonitrile)palladium chloride, palladium trifluoromethanesulfonate and palladium acetate, such as palladium chloride; (5) In step S6, the molar ratio of the palladium catalyst to the compound represented by formula 4 is (0.01-0.5):1, for example 0.04:1; (6) In step S6, the phosphine ligand is one or more of tri-tert-butyl phosphine, tricyclohexyl phosphine, di(1-adamantyl)-n-butyl phosphine, diadamantyl isopropyl phosphine and diadamantyl propyl phosphine, for example, di(1-adamantyl)-n-butyl phosphine; (7) In step S6, the molar ratio of the phosphine ligand to the compound represented by formula 4 is (0.01-0.5):1, for example 0.06:1; (8) In step S6, the base is an alkali metal carbonate, such as potassium carbonate or potassium phosphate; (9) In step S6, the molar ratio of the base to the compound represented by formula 4 is (1-5):1, for example, 2:1; (10) In step S6, the temperature of the dearomatization cyclization reaction is 100°C-180°C, for example, 140°C; (11) In step S6, the dearomatization reaction time is 3-10 hours, for example 6 hours; and (12) In step S6, after the dearomatization reaction is completed, the following post-treatment steps are further included: one or more of filtration, concentration, drying and purification; the concentration can be reduced pressure distillation; the purification can be column chromatography, and the eluent of the column chromatography can be a mixed solvent of dichloromethane and methanol, for example, the volume ratio of dichloromethane to methanol is (150-100):
1.
15. The method for preparing the compound represented by formula A8 according to claim 13, characterized in that: The method for preparing the compound shown in Formula 5 also includes the method for preparing the compound shown in Formula 4. The method comprises the following steps S5: in a solvent, the compound represented by formula 4-3' and di-tert-butyl carbonic anhydride react as shown in the following formula to obtain a compound represented by formula 4, 16. The method for preparing the compound represented by formula A8 according to claim 15, characterized in that: It meets one or more of the following conditions: (1) In step S5, the solvent is a chlorinated alkane solvent, and the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; (2) In step S5, the molar volume ratio of the compound represented by formula 4-3' to the solvent is (0.01-1) mol:1L, for example, 0.09 mol:1L; (3) In step S5, the molar ratio of the di-tert-butyl carbonic anhydride to the compound represented by formula 4-3' is (1-3):1, for example, 1.08:1; (4) In step S5, the reaction temperature is 10-30°C, for example, 25°C; (5) In step S5, the reaction time is 1-5 h, for example 3 h; (6) In step S5, after the reaction is completed, the following post-treatment steps are further included: one or more of concentration, crystallization, filtration and drying; the concentration can be reduced pressure distillation; the solvent for the crystallization can be methanol; and the drying can be oven drying.
17. The method for preparing the compound of formula A8 according to claim 15, characterized in that: The method for preparing the compound of Formula 4 also includes a method for preparing the compound of Formula 4-3', which specifically includes the following steps S4': in a solvent, the compound of Formula 4-3 reacts with a base as shown in the following formula to obtain the compound of Formula 4-3', 18. The method for preparing the compound of formula A8 according to claim 17, characterized in that: It meets one or more of the following conditions: (1) In step S4', the solvent is a chlorinated hydrocarbon solvent; the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; (2) In step S4', the molar volume ratio of the compound represented by formula 4-3 to the solvent is (0.01-1) mol:1L, for example, 0.13 mol:1L; (3) In step S4', the base is an inorganic base, such as potassium bicarbonate, or an aqueous solution of potassium bicarbonate; (4) In step S4', the molar ratio of the base to the compound shown in formula 4-3 is (1-10):1, for example (4-6):1, and then For example, 5:1; (5) In step S4', the reaction temperature is 20-30°C, for example, 25°C; (6) In step S4', the reaction time is 0.3-12 h, for example 1 h; and (7) In step S4', after the reaction is completed, the following post-treatment step is further included: extraction; the extraction solvent can be dichloromethane.
19. The method for preparing the compound of formula A8 according to claim 17, characterized in that: The method for preparing the compound shown in Formula 4-3' also includes the method for preparing the compound shown in Formula 4-3, which specifically includes the following step S4: in a solvent, the compound shown in Formula 4-2 and D-(+)-di-p-methylbenzoyltartaric acid react as shown in the following formula to obtain the compound shown in Formula 4-3, 20. The method for preparing the compound of formula A8 according to claim 19, characterized in that: It meets one or more of the following conditions: (1) In step S4, the reaction is carried out in an open system, which may be an air system; (2) In step S4, the solvent is an alcohol solvent, for example, one or more selected from methanol, ethanol and isopropanol; another example is methanol; (3) In step S4, the molar volume ratio of the compound represented by formula 4-2 to the solvent is (0.1-1) mol:1L, for example, 0.62 mol:1 or 0.6 mol:1; (4) In step S4, the molar ratio of the D-(+)-di-p-methylbenzoyltartaric acid to the compound of formula 4-2 is (1-3):1, for example (0.9-1.5):1, and for example 1.05:1 or 1.07:1; (5) In step S4, the reaction temperature is 50-100°C, for example 70°C-100°C, and for example 85°C; (6) In step S4, the reaction time is 3-12 h, for example 8 h; (7) Step S4 further comprises the following steps: mixing the compound represented by Formula 4-2 with the solvent, and then adding the D-(+)-di-p-methylbenzoyltartaric acid; and (8) In step S4, after the reaction is completed, the following post-processing step is also included: filtration.
21. The method for preparing the compound of formula A8 according to claim 19, characterized in that: The method for preparing the compound shown in Formula 4-3 also includes the method for preparing the compound shown in Formula 4-2, which specifically includes the following step S3: in a solvent, in the presence of an organic base, the compound shown in Formula 4-1 is subjected to a decarbamate protection reaction as shown in the following formula to obtain the compound shown in Formula 4-2, The organic base is potassium alkoxide and / or sodium alkoxide.
22. The method for preparing the compound of formula A8 according to claim 21, characterized in that: It meets one or more of the following conditions: (1) In step S3, the solvent is an ether solvent and / or a chlorinated hydrocarbon solvent, such as an ether solvent; the ether solvent may be one or more of tetrahydrofuran, 1,4-dioxane, diethyl ether and methyl tert-butyl ether, such as tetrahydrofuran; (2) In step S3, the molar volume ratio of the compound represented by formula 4-1 to the solvent is (0.01-3) mol:1L, for example (0.1-1) mol:1L, for example 0.31 mol:1L or 0.35 mol:1L; (3) In step S3, the potassium alcoholate is potassium methoxide, potassium ethoxide or potassium tert-butoxide, for example potassium tert-butoxide; (4) In step S3, the sodium alkoxide is sodium methoxide, sodium ethoxide or sodium tert-butoxide; (5) In step S3, the reaction system further includes an inorganic base; the inorganic base may be potassium hydroxide and / or sodium hydroxide, for example, potassium hydroxide; The molar ratio of the organic base to the inorganic base may be (0.5-2):1, for example 1:1; (6) In step S3, the molar ratio of the organic base to the compound of formula 4-1 is (0.05-5):1, for example (1-3):1, and for example 2:1 or 1.77:1; (7) In step S3, the temperature of the decarbamate protection reaction is 60-80° C., for example 70° C.; (8) Step S3 further comprises the following steps: mixing the compound represented by Formula 4-1 with the solvent, and then adding the organic base; (9) In step S3, the reaction time of decarbamate protection is 5-24 hours, for example 8 hours; and (10) In step S3, after the decarbamate protection reaction is completed, the following post-treatment steps are further included: one or more of quenching, extraction and concentration; the quenching solvent can be water; the extraction solvent can be dichloromethane; the concentration can be reduced pressure concentration.
23. The method for preparing the compound of formula A8 according to claim 21, characterized in that: The organic base is sodium alkoxide, such as sodium tert-butoxide.
24. The method for preparing the compound of formula A8 according to claim 21, characterized in that: The method for preparing the compound shown in Formula 4-2 also includes the method for preparing the compound shown in Formula 4-1, which specifically includes the following steps S2: in a solvent, in the presence of a base, the compound shown in Formula 3' undergoes a reaction as shown in the following formula to obtain the compound shown in Formula 4-1, 25. The method for preparing the compound of formula A8 as claimed in claim 24, characterized in that: It meets one or more of the following conditions: (1) In step S2, the solvent is an alcohol solvent, such as methanol and / or ethanol, and another example is ethanol; (2) In step S2, the molar volume ratio of the compound represented by formula 3 to the solvent is (0.1-1) mol:1L, for example, 0.62 mol:1L; (3) In step S2, the base is an inorganic base, such as potassium hydroxide; (4) In step S2, the molar ratio of the base to the compound represented by formula 3 is (1-3):1, for example, 2:1; (5) In step S2, the reaction temperature is 30°C-70°C, for example, 50°C; (6) In step S2, the reaction time is 1-10 hours, for example 3 hours; and (7) In step S2, after the reaction is completed, the following post-treatment steps are also included: one or more of quenching, pulping and drying; the quenching solvent can be water; the drying can be oven drying; the pulping solvent can be methanol.
26. The method for preparing the compound of formula A8 as claimed in claim 24, characterized in that: The method for preparing the compound of formula 4-1 also includes a method for preparing the compound of formula 3', which specifically includes the following steps S2': in a solvent, in the presence of a base, the compound of formula 3 and benzyl bromide react as shown in the following formula to obtain the compound of formula 3', 27. The method for preparing the compound of formula A8 according to claim 26, characterized in that: It meets one or more of the following conditions: (1) In step S2', the reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, for example, nitrogen; (2) In step S2', the solvent is an amide solvent, such as N,N-dimethylformamide (DMF) and / or N,N-dimethylacetamide (DMA), and another example is N,N-dimethylformamide; (3) In step S2', the molar volume ratio of the compound represented by formula 3 to the solvent is (0.1-1) mol:1L, for example, 0.62 mol:1L; (4) In step S2', the base is an alkali metal carbonate, such as potassium carbonate; (5) In step S2', the molar ratio of the base to the compound represented by formula 3 is (1-3):1, for example, 2:1; (6) In step S2', the molar ratio of the benzyl bromide to the compound represented by formula 3 is (1-3):1, for example, 2:1; (7) In step S2', the reaction temperature is 10°C-30°C, for example, 25°C; (8) In step S2', the reaction time is 3-10 hours, for example 6 hours; and (9) In step S2', after the reaction is completed, the following post-treatment step is further included: crystallization; the solvent for the crystallization can be water.
28. The method for preparing the compound of formula A8 according to claim 26, characterized in that: The method for preparing the compound of formula 3' also includes a method for preparing the compound of formula 3, which specifically includes the following steps S1: in a solvent, in the presence of an acid, the compound of formula 1 and the compound of formula 2 undergo a condensation cyclization reaction as shown in the following formula to obtain a compound of formula 3, The acid is one or more of methanesulfonic acid, trifluoroacetic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate.
29. The method for preparing the compound of formula A8 as claimed in claim 28, characterized in that: It meets one or more of the following conditions: (1) In step S1, the condensation cyclization reaction is carried out in an open system; the open system may be an air system; (2) In step S1, the solvent is a chlorinated alkane and / or an amide, such as a chlorinated alkane organic solvent; the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; (3) In step S1, the molar volume ratio of the compound represented by Formula 1 to the solvent is (0.1-5) mol:1L, for example (0.1-2) mol:1L, and another example is 0.78 mol:1L; (4) In step S1, the molar ratio of the acid to the compound of formula 1 is (1-5):1, for example (1-3):1, and for example 2:1; (5) In step S1, the acid is p-toluenesulfonic acid and / or p-toluenesulfonic acid monohydrate, for example, p-toluenesulfonic acid monohydrate; (6) In step S1, the molar ratio of the compound represented by formula 2 to the compound represented by formula 1 is (1-1.5):1, for example, 1.4:1; (7) In step S1, the temperature of the condensation cyclization reaction is 0-30°C, for example, 25°C; (8) In step S1, the condensation cyclization reaction time is 2-24 hours, for example 16 hours; and (9) In step S1, after the reaction is completed, the following post-treatment steps are further included: one or more of quenching, drying, concentration and purification; the quenching solvent may be water; the drying desiccant may be anhydrous sodium sulfate; the concentration may be reduced pressure distillation; the purification may be recrystallization, and the recrystallization solvent may be a mixed solvent of ethyl acetate and petroleum ether, for example, the volume ratio of ethyl acetate to petroleum ether is 2:
1.
30. The method for preparing the compound of formula A8 as claimed in claim 28, characterized in that: The method for preparing the compound of Formula 3 also includes the method for preparing the compound of Formula 1, which specifically includes the following steps S1-1: In a solvent, the compound of Formula 1-2 and ethyl chloroformate react as shown in the following formula to obtain the compound of Formula 1, 31. The method for preparing the compound of formula A8 as claimed in claim 30, characterized in that: It meets one or more of the following conditions: (1) In step S1-1, the solvent is an ether solvent, such as tetrahydrofuran; (2) In step S1-1, the molar volume ratio of the compound represented by formula 1-2 to the solvent is (0.1-5) mol:1L, for example (0.1-1) mol:1L, and another example is 0.1 mol:1L; (3) In step S1-1, the molar ratio of the ethyl chloroformate to the compound represented by formula 1-2 is (1-5):1, for example (1-3):1, and for example 2.2:1; (4) In step S1-1, the reaction temperature is 10-30°C, for example, 25°C; (5) In step S1-1, the reaction time is 1-30 hours, for example 16 hours; and (6) In step S1-1, after the reaction is completed, the following post-treatment steps are further included: one or more of quenching, extraction, drying and concentration; the quenching solvent may be water; the drying desiccant may be anhydrous sodium sulfate; the concentration may be reduced pressure distillation; the purification may be recrystallization, and the extraction solvent may be ethyl acetate.
32. A method for preparing a compound as shown in formula A9, characterized in that: The method comprises the following steps S14: in a solvent, in the presence of a demethylating agent, subjecting the compound represented by formula A8 to a demethylation reaction as shown in the following formula to obtain a compound represented by formula A9, The method for preparing the compound as shown in Formula A9 also includes the method for preparing the compound as shown in Formula A8, which specifically includes the following steps S11, S12 and S13: S11: In a solvent, in the presence of a catalyst, the compound represented by Formula 7 is subjected to a hydrogenation reaction represented by the following formula with hydrogen to obtain a compound represented by Formula 8-1, S12: In a solvent, in the presence of a deprotection agent, the compound represented by Formula 8-1 undergoes a deprotection reaction represented by the following formula to obtain a compound represented by Formula 8-2, S13: In a solvent, in the presence of a base, the compound represented by Formula 8-2 and the compound represented by Formula SM1 undergo a substitution reaction as shown in the following formula to obtain a compound represented by Formula A8, Among them, X and R 1 The definition as described in any one of claims 1 to 31; The method for preparing the compound represented by formula A8 can be as described in any one of claims 1 to 31.
33. The method for preparing the compound of formula A9 as claimed in claim 32, characterized in that: It meets one or more of the following conditions: (1) In step S14, the compound represented by formula A8 is The compound shown in formula A9 is (2) In step S14, the solvent is a chlorinated alkane, and the chlorinated alkane solvent may be one or more of dichloromethane, 1,2-dichloroethane and chloroform, such as dichloromethane; (3) In step S14, the molar volume ratio of the compound represented by formula A8 to the solvent is (0.01-0.1) mol:1L, for example, 0.045 mol:1L; (4) In step S14, the demethylation reaction is carried out under the protection of an inert gas; the inert gas may be nitrogen and / or argon, for example, nitrogen; (5) In step S14, the demethylation agent is boron trichloride and / or boron tribromide, for example, boron tribromide; (6) In step S14, the molar ratio of the demethylation agent to the compound represented by formula A8 is (5-10):1, for example (6-8):1, and for example 7:1; (7) In step S14, the temperature of the demethylation reaction is -20-25°C, for example, 10°C; (8) In step S14, the demethylation reaction time is 1-5 hours, for example 2 hours; and (9) In step S14, after the demethylation reaction is completed, the following post-treatment steps are also included: one or more of quenching, adjusting pH, extraction, drying, concentration and purification; the quenching solvent may be a saturated aqueous solution of ammonium chloride; the pH adjustment solvent may be a saturated 10% NaHCO3 aqueous solution; the extraction solvent may be dichloromethane; the drying desiccant may be anhydrous sodium sulfate; the concentration may be reduced pressure distillation; the purification may be column chromatography; the eluent of the column chromatography may be a mixed solvent of dichloromethane and methanol, for example, the volume ratio of dichloromethane to methanol is 50:
1.
34. A method for preparing a compound as shown in formula 4-3', characterized in that: It comprises the following steps S4': in a solvent, the compound represented by formula 4-3 reacts with a base as shown in the following formula to obtain a compound represented by formula 4-3', The conditions and operations of step S4' may be as described in claim 18, and the method for preparing the compound represented by formula 4-3' may be as described in any one of claims 19-31.
35. A method for preparing a compound as shown in formula 4-2, characterized in that: The method comprises the following steps S3: in a solvent, in the presence of an organic base, the compound represented by Formula 4-1 undergoes a reaction represented by the following formula to obtain a compound represented by Formula 4-2, The organic base is potassium alkoxide and / or sodium alkoxide; The conditions and operations of step S3 may be as described in any one of claims 22 or 23; the method for preparing the compound shown in formula 4-2 may be as described in any one of claims 24-31.
36. A method for preparing a compound as shown in formula 3, characterized in that: The method comprises the following steps S1: in a solvent, in the presence of an acid, the compound represented by Formula 1 and the compound represented by Formula 2 are reacted as shown in the following formula to obtain a compound represented by Formula 3. The acid is one or more of methanesulfonic acid, trifluoroacetic acid, p-toluenesulfonic acid and p-toluenesulfonic acid monohydrate; The conditions and operations of step S1 may be as described in claim 29; the method for preparing the compound shown in formula 3 may be as described in any one of claims 30 or 31.
37. A compound as shown in formula 7, 6-2, 5, 4, 4-3, 4-1, 3 or 1,
Citation Information
Patent Citations
Oxycodone compounds, and intermediates and preparation methods thereof
CN111205296A
Oxycodone compound as well as intermediate and preparation method thereof
CN114573508A
Morphinan derivs - prepd by acid cyclisation of substd n-formyloctahydroisoquinoline, show analgesic and morphin-antagonist
DE2311881A1
Processes for the production of (+)-'NAL' morphinan compounds
WO2009079013A1
Method for preparing codeine and derivative and intermediate thereof
WO2023164889A1
Cited By
Preparation method and intermediate of nalmefene compound
CN122647492A
